Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:mercury dibromide
go back to main search page
Accession:CHEBI:49639 term browser browse the term
Definition:A mercury coordination entity composed of mercury and bromine with the formula HgBr2.
Synonyms:exact_synonym: mercury(2+) bromide;   mercury(II) bromide
 related_synonym: DIBROMOMERCURY;   Formula=Br2Hg;   HgBr2;   InChI=1S/2BrH.Hg/h2*1H;/q;;+2/p-2;   InChIKey=NGYIMTKLQULBOO-UHFFFAOYSA-L;   SMILES=Br[Hg]Br;   mercuric bromide;   mercury bromide
 alt_id: CHEBI:33212;   CHEBI:49638
 xref: CAS:7789-47-1;   Gmelin:277818
 xref_mesh: MESH:C042720
 xref: PDBeChem:HG2;   PMID:15074688;   Reaxys:8127939;   Wikipedia:Mercury(II)_bromide



show annotations for term's descendants           Sort by:
 
mercury dibromide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G A1bg alpha-1-B glycoprotein decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of A1BG mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of A1BG mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:92,493,934...92,498,460
Ensembl chr 7:92,494,372...92,498,097
JBrowse link
G Abcb6 ATP binding cassette subfamily B member 6 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ABCB6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCB6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:76,668,554...76,677,263
Ensembl chr 9:76,668,554...76,676,924
JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of ABCC4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABCC4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ABCG2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCG2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
JBrowse link
G Abhd14a abhydrolase domain containing 14A decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of ABHD14A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABHD14A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:107,079,139...107,089,004
Ensembl chr 8:107,079,144...107,086,985
JBrowse link
G Abhd3 abhydrolase domain containing 3, phospholipase increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ABHD3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABHD3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:1,723,203...1,778,488
Ensembl chr18:1,720,718...1,803,428
JBrowse link
G Acp3 acid phosphatase 3 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACP3 mRNA CTD PMID:27188386 NCBI chr 8:104,905,570...104,956,146
Ensembl chr 8:104,905,586...104,954,236
JBrowse link
G Acsl1 acyl-CoA synthetase long-chain family member 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSL1 mRNA CTD PMID:27188386 NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
JBrowse link
G Actg2 actin gamma 2, smooth muscle multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACTG2 mRNA CTD PMID:27188386 NCBI chr 4:116,021,832...116,046,475
Ensembl chr 4:116,021,832...116,046,465
JBrowse link
G Actn3 actinin alpha 3 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of ACTN3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ACTN3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:202,159,081...202,175,012
Ensembl chr 1:202,159,082...202,175,012
JBrowse link
G Adam28 ADAM metallopeptidase domain 28 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAM28 mRNA CTD PMID:27188386 NCBI chr15:43,774,463...43,840,726
Ensembl chr15:42,944,467...43,840,672
JBrowse link
G Adam9 ADAM metallopeptidase domain 9 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ADAM9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAM9 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:67,022,538...67,101,647
Ensembl chr16:67,022,655...67,100,917
JBrowse link
G Adamts1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ADAMTS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
JBrowse link
G Adamts12 ADAM metallopeptidase with thrombospondin type 1 motif, 12 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ADAMTS12 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS12 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:60,032,873...60,327,629
Ensembl chr 2:60,032,873...60,327,629
JBrowse link
G Adamts2 ADAM metallopeptidase with thrombospondin type 1 motif, 2 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAMTS2 mRNA CTD PMID:27188386 NCBI chr10:34,920,996...35,126,465
Ensembl chr10:34,921,049...35,123,821
JBrowse link
G Adamts20 ADAM metallopeptidase with thrombospondin type 1 motif, 20 decreases expression ISO mercuric bromide results in decreased expression of ADAMTS20 mRNA CTD PMID:26272509 NCBI chr 7:125,396,227...125,528,020
Ensembl chr 7:125,397,734...125,527,777
JBrowse link
G Adcy2 adenylate cyclase 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ADCY2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCY2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:34,375,639...34,822,237
Ensembl chr 1:34,375,895...34,822,236
JBrowse link
G Adcyap1r1 ADCYAP receptor type I decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of ADCYAP1R1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADCYAP1R1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:84,593,558...84,642,700
Ensembl chr 4:84,593,892...84,642,700
JBrowse link
G Adgrg2 adhesion G protein-coupled receptor G2 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of ADGRG2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:34,297,402...34,422,590
Ensembl chr  X:34,297,402...34,422,609
JBrowse link
G Adgrg6 adhesion G protein-coupled receptor G6 multiple interactions
increases expression
ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRG6 mRNA
mercuric bromide results in increased expression of ADGRG6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:8,812,889...8,954,239
Ensembl chr 1:8,812,904...8,954,123
JBrowse link
G Adm adrenomedullin multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADM mRNA CTD PMID:27188386 NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
JBrowse link
G Afap1l2 actin filament associated protein 1-like 2 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of AFAP1L2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AFAP1L2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:255,964,238...256,060,828
Ensembl chr 1:255,964,238...256,060,820
JBrowse link
G Afp alpha-fetoprotein multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AFP mRNA CTD PMID:27188386 NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
JBrowse link
G Agtr1a angiotensin II receptor, type 1a increases expression ISO mercuric bromide results in increased expression of AGTR1 mRNA CTD PMID:27188386 NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
JBrowse link
G Ajap1 adherens junctions associated protein 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of AJAP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AJAP1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:163,907,846...164,021,004
Ensembl chr 5:163,907,847...164,020,317
JBrowse link
G Akr1c1 aldo-keto reductase family 1, member C1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of AKR1C1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of AKR1C2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of AKR1C3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
JBrowse link
G Alcam activated leukocyte cell adhesion molecule increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ALCAM mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALCAM mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:48,336,123...48,536,296
Ensembl chr11:48,336,169...48,537,954
JBrowse link
G Aldh1a3 aldehyde dehydrogenase 1 family, member A3 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ALDH1A3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1A3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436
JBrowse link
G Aldh1l2 aldehyde dehydrogenase 1 family, member L2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ALDH1L2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1L2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:20,254,196...20,305,793
Ensembl chr 7:20,254,233...20,305,776
JBrowse link
G Aldh3b2 aldehyde dehydrogenase 3 family, member B2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ALDH3B2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH3B2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:201,250,260...201,264,699
Ensembl chr 1:201,253,157...201,264,705
JBrowse link
G Alkal2 ALK and LTK ligand 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ALKAL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALKAL2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:47,495,645...47,505,235
Ensembl chr 6:47,495,782...47,505,234
JBrowse link
G Alpk2 alpha-kinase 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ALPK2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALPK2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:58,775,603...58,906,150
Ensembl chr18:58,775,605...58,906,258
JBrowse link
G Ambp alpha-1-microglobulin/bikunin precursor increases expression
multiple interactions
ISO mercuric bromide results in increased expression of AMBP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMBP mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:76,568,094...76,578,416
Ensembl chr 5:76,568,094...76,578,331
JBrowse link
G Amer2 APC membrane recruitment protein 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of AMER2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMER2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:34,525,090...34,535,660
Ensembl chr15:34,524,542...34,528,455
JBrowse link
G Amigo2 adhesion molecule with Ig like domain 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of AMIGO2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMIGO2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:128,391,493...128,394,589
Ensembl chr 7:128,390,412...128,394,695
JBrowse link
G Ank1 ankyrin 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ANK1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANK1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:68,876,294...69,054,812
Ensembl chr16:68,877,504...69,054,759
JBrowse link
G Ankrd1 ankyrin repeat domain 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ANKRD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:233,815,851...233,834,891
Ensembl chr 1:233,815,851...233,834,919
JBrowse link
G Ankrd33b ankyrin repeat domain 33B increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ANKRD33B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD33B mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:82,277,604...82,359,420
Ensembl chr 2:82,283,108...82,358,872
JBrowse link
G Antxr1 ANTXR cell adhesion molecule 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ANTXR1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANTXR1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:119,590,770...119,778,232
Ensembl chr 4:119,590,771...119,778,232
JBrowse link
G Anxa1 annexin A1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ANXA1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
JBrowse link
G Anxa2 annexin A2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ANXA2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658
JBrowse link
G Anxa3 annexin A3 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ANXA3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617
JBrowse link
G Anxa4 annexin A4 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ANXA4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161
JBrowse link
G Anxa9 annexin A9 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA9 mRNA CTD PMID:27188386 NCBI chr 2:182,873,185...182,884,501
Ensembl chr 2:182,872,929...182,883,374
JBrowse link
G Aox1 aldehyde oxidase 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of AOX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AOX1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770
JBrowse link
G Apba2 amyloid beta precursor protein binding family A member 2 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of APBA2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APBA2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:118,053,270...118,286,858
Ensembl chr 1:118,103,219...118,285,699
JBrowse link
G Apcdd1 APC down-regulated 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of APCDD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APCDD1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:56,385,398...56,416,065
Ensembl chr18:56,385,264...56,416,070
JBrowse link
G Apoa1 apolipoprotein A1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of APOA1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APOA1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
JBrowse link
G Apoa2 apolipoprotein A2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of APOA2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APOA2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355
JBrowse link
G Arap2 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ARAP2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] affects the expression of ARAP2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:46,717,657...46,917,326
Ensembl chr14:46,718,760...46,917,154
JBrowse link
G Arhgap18 Rho GTPase activating protein 18 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ARHGAP18 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP18 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:18,403,531...18,637,306
Ensembl chr 1:18,403,537...18,637,256
JBrowse link
G Arhgdib Rho GDP dissociation inhibitor beta multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGDIB mRNA CTD PMID:27188386 NCBI chr 4:169,822,951...169,841,884
Ensembl chr 4:169,822,952...169,841,658
JBrowse link
G Arhgef25 Rho guanine nucleotide exchange factor 25 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of ARHGEF25 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGEF25 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:63,005,938...63,013,325
Ensembl chr 7:63,005,940...63,013,719
JBrowse link
G Arhgef9 Cdc42 guanine nucleotide exchange factor 9 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of ARHGEF9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGEF9 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:59,919,560...60,077,538
Ensembl chr  X:59,920,870...60,077,513
JBrowse link
G Arid5b AT-rich interaction domain 5B increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ARID5B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARID5B mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr20:20,307,731...20,490,746
Ensembl chr20:20,307,731...20,487,433
JBrowse link
G Arl9 ADP-ribosylation factor like GTPase 9 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of ARL9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARL9 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:31,157,585...31,166,803
Ensembl chr14:31,157,586...31,166,699
JBrowse link
G Arrb1 arrestin, beta 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ARRB1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061
JBrowse link
G Arrdc2 arrestin domain containing 2 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of ARRDC2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARRDC2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:18,601,897...18,606,029
Ensembl chr16:18,601,897...18,606,029
JBrowse link
G Arx aristaless related homeobox decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of ARX mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARX mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:58,016,233...58,028,149
Ensembl chr  X:58,016,233...58,028,142
JBrowse link
G Ascc3 activating signal cointegrator 1 complex subunit 3 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ASCC3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCC3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr20:53,510,137...53,795,446
Ensembl chr20:53,510,184...53,790,165
JBrowse link
G Asf1a anti-silencing function 1A histone chaperone increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ASF1A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASF1A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr20:32,893,962...32,908,808
Ensembl chr20:32,893,573...32,908,808
JBrowse link
G Asic1 acid sensing ion channel subunit 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of ASIC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASIC1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:130,798,317...130,828,535
Ensembl chr 7:130,799,917...130,828,541
JBrowse link
G Asns asparagine synthetase (glutamine-hydrolyzing) increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ASNS mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASNS mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
JBrowse link
G Asphd1 aspartate beta-hydroxylase domain containing 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of ASPHD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASPHD1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:181,552,974...181,556,842
Ensembl chr 1:181,552,884...181,556,090
JBrowse link
G Astn1 astrotactin 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of ASTN1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASTN1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:70,537,423...70,855,440
Ensembl chr13:70,537,703...70,855,440
JBrowse link
G Atf3 activating transcription factor 3 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATF3 mRNA CTD PMID:27188386 NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
JBrowse link
G Atl3 atlastin GTPase 3 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of ATL3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATL3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:204,680,958...204,727,360
Ensembl chr 1:204,680,968...204,723,354
JBrowse link
G Atp10d ATPase phospholipid transporting 10D (putative) increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ATP10D mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP10D mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:35,911,728...36,012,549
Ensembl chr14:35,912,141...36,012,564
JBrowse link
G Atp6v1c1 ATPase H+ transporting V1 subunit C1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ATP6V1C1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V1C1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:69,834,464...69,872,278
Ensembl chr 7:69,834,463...69,872,278
JBrowse link
G Atp8a1 ATPase phospholipid transporting 8A1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of ATP8A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP8A1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:40,315,013...40,557,572
Ensembl chr14:40,315,049...40,554,611
JBrowse link
G Atp8b1 ATPase phospholipid transporting 8B1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ATP8B1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396
JBrowse link
G B9d1 B9 domain containing 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of B9D1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B9D1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:46,186,222...46,196,309
Ensembl chr10:46,186,691...46,196,008
JBrowse link
G Bag2 BAG cochaperone 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of BAG2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:35,970,033...35,980,677
Ensembl chr 9:35,970,033...35,980,721
JBrowse link
G Bag3 BAG cochaperone 3 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of BAG3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858
JBrowse link
G Bambi BMP and activin membrane-bound inhibitor increases expression
multiple interactions
ISO mercuric bromide results in increased expression of BAMBI mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060
JBrowse link
G Bbs9 Bardet-Biedl syndrome 9 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of BBS9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BBS9 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:21,013,865...21,437,934
Ensembl chr 8:21,013,944...21,437,930
JBrowse link
G Bche butyrylcholinesterase decreases expression ISO mercuric bromide results in decreased expression of BCHE mRNA CTD PMID:26272509 NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
JBrowse link
G Bcl11a BAF chromatin remodeling complex subunit BCL11A increases expression
multiple interactions
ISO mercuric bromide results in increased expression of BCL11A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:98,029,018...98,124,181
Ensembl chr14:98,030,461...98,124,180
JBrowse link
G Bcl2l11 Bcl2-like 11 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of BCL2L11 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
JBrowse link
G Bco1 beta-carotene oxygenase 1 multiple interactions
decreases expression
ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCO1 mRNA
mercuric bromide results in decreased expression of BCO1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:45,149,250...45,186,102
Ensembl chr19:45,149,265...45,186,101
JBrowse link
G Bdnf brain-derived neurotrophic factor multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BDNF mRNA CTD PMID:27188386 NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
JBrowse link
G Bend4 BEN domain containing 4 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of BEND4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEND4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:40,753,048...40,788,686
Ensembl chr14:40,753,077...40,783,504
JBrowse link
G Bend6 BEN domain containing 6 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of BEND6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEND6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:36,081,033...36,135,309
Ensembl chr 9:36,081,484...36,135,228
JBrowse link
G Best4 bestrophin 4 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of BEST4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEST4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:130,622,194...130,629,045
Ensembl chr 5:130,623,438...130,627,099
JBrowse link
G Bhlhe40 basic helix-loop-helix family, member e40 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of BHLHE40 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BHLHE40 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774
JBrowse link
G Bmp4 bone morphogenetic protein 4 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of BMP4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
JBrowse link
G Bmp5 bone morphogenetic protein 5 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of BMP5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:76,517,164...76,639,925
Ensembl chr 8:76,517,164...76,639,925
JBrowse link
G Bmp6 bone morphogenetic protein 6 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of BMP6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:26,318,121...26,469,034
Ensembl chr17:26,318,569...26,470,365
JBrowse link
G Bmp7 bone morphogenetic protein 7 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of BMP7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP7 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788
JBrowse link
G Bnc1 basonuclin 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of BNC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNC1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:135,917,676...135,943,333
Ensembl chr 1:135,917,687...135,943,333
JBrowse link
G Bnipl BCL2 interacting protein like multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNIPL mRNA CTD PMID:27188386 NCBI chr 2:182,818,593...182,830,421
Ensembl chr 2:182,818,595...182,828,588
JBrowse link
G Boc BOC cell adhesion associated, oncogene regulated decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of BOC mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BOC mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:56,122,697...56,198,060
Ensembl chr11:56,122,750...56,198,059
JBrowse link
G Bspry B-box and SPRY domain containing multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BSPRY mRNA CTD PMID:27188386 NCBI chr 5:75,927,397...75,949,585
Ensembl chr 5:75,927,405...75,949,583
JBrowse link
G Bst2 bone marrow stromal cell antigen 2 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of BST2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BST2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:18,217,404...18,220,979
Ensembl chr16:18,217,407...18,220,979
JBrowse link
G Btg2 BTG anti-proliferation factor 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of BTG2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BTG2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
JBrowse link
G Btg3 BTG anti-proliferation factor 3 increases expression ISO mercuric bromide results in increased expression of BTG3 mRNA CTD PMID:26272509 NCBI chr11:17,030,156...17,046,069
Ensembl chr11:17,030,160...17,046,170
JBrowse link
G C11h3orf70 similar to human chromosome 3 open reading frame 70 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of C3ORF70 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C3ORF70 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:79,345,792...79,396,140
Ensembl chr11:79,345,304...79,396,142
JBrowse link
G C16h4orf47 similar to human chromosome 4 open reading frame 47 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of C4ORF47 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C4ORF47 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:46,291,075...46,315,616
Ensembl chr16:46,291,311...46,315,625
JBrowse link
G C1s complement C1s increases expression
multiple interactions
ISO mercuric bromide results in increased expression of C1S mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1S mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:157,430,249...157,442,438
Ensembl chr 4:157,430,117...157,442,303
JBrowse link
G C8h11orf52 similar to human chromosome 11 open reading frame 52 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF52 mRNA CTD PMID:27188386 NCBI chr 8:51,081,342...51,088,333
Ensembl chr 8:51,081,342...51,094,533
JBrowse link
G C9h6orf141 similar to human chromosome 6 open reading frame 141 decreases expression ISO mercuric bromide results in decreased expression of C6ORF141 mRNA CTD PMID:26272509 NCBI chr 9:20,024,916...20,029,094
Ensembl chr 9:20,024,916...20,029,094
JBrowse link
G Cab39l calcium binding protein 39-like increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CAB39L mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAB39L mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:33,606,588...33,710,518
Ensembl chr15:33,606,694...33,743,545
JBrowse link
G Cachd1 cache domain containing 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CACHD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACHD1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:115,411,833...115,637,312
Ensembl chr 5:115,411,071...115,657,505
JBrowse link
G Cacnb2 calcium voltage-gated channel auxiliary subunit beta 2 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA CTD PMID:27188386 NCBI chr17:77,564,630...77,910,000
Ensembl chr17:77,564,460...77,909,106
JBrowse link
G Cadm2 cell adhesion molecule 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CADM2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CADM2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:4,548,367...5,525,420
Ensembl chr11:4,555,159...5,525,400
JBrowse link
G Calb1 calbindin 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CALB1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALB1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431
JBrowse link
G Camk2d calcium/calmodulin-dependent protein kinase II delta increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CAMK2D mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAMK2D mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:215,023,785...215,287,351
Ensembl chr 2:215,024,004...215,286,178
JBrowse link
G Camk2n1 calcium/calmodulin-dependent protein kinase II inhibitor 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CAMK2N1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAMK2N1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:150,674,819...150,676,600
Ensembl chr 5:150,673,507...150,676,600
JBrowse link
G Car13 carbonic anhydrase 13 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA13 mRNA CTD PMID:27188386 NCBI chr 2:86,928,401...86,959,525
Ensembl chr 2:86,928,383...86,959,525
JBrowse link
G Car4 carbonic anhydrase 4 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CA4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CA4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:69,827,945...69,836,501
Ensembl chr10:69,827,945...69,836,501
JBrowse link
G Cars cysteinyl-tRNA synthetase increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CARS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CARS1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:198,753,689...198,796,016
Ensembl chr 1:198,753,691...198,795,941
JBrowse link
G Casp3 caspase 3 decreases activity ISO mercuric bromide results in decreased activity of CASP3 protein CTD PMID:26272509 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp8 caspase 8 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CASP8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
JBrowse link
G Cav1 caveolin 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CAV1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAV1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
JBrowse link
G Cav2 caveolin 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CAV2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAV2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:45,616,766...45,624,144
Ensembl chr 4:45,616,712...45,624,244
JBrowse link
G Cc2d1b coiled-coil and C2 domain containing 1B increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CC2D1B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CC2D1B mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:123,353,289...123,367,343
Ensembl chr 5:123,353,292...123,367,318
JBrowse link
G Ccar2 cell cycle and apoptosis regulator 2 decreases expression ISO mercuric bromide results in decreased expression of CCAR2 mRNA CTD PMID:26272509 NCBI chr15:45,212,797...45,228,001
Ensembl chr15:45,212,803...45,227,636
JBrowse link
G Ccbe1 collagen and calcium binding EGF domains 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CCBE1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCBE1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:59,579,851...59,823,977
Ensembl chr18:59,580,768...59,824,400
JBrowse link
G Ccdc102a coiled-coil domain containing 102A decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CCDC102A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC102A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:10,102,543...10,118,657
Ensembl chr19:10,103,361...10,118,657
JBrowse link
G Ccdc113 coiled-coil domain containing 113 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CCDC113 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC113 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:9,497,000...9,516,917
Ensembl chr19:9,496,886...9,516,923
JBrowse link
G Ccdc136 coiled-coil domain containing 136 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CCDC136 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC136 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:57,997,825...58,027,598
Ensembl chr 4:57,997,853...58,027,646
JBrowse link
G Ccdc177 coiled-coil domain containing 177 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CCDC177 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC177 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:100,400,010...100,411,221
Ensembl chr 6:100,404,413...100,412,850
JBrowse link
G Cckbr cholecystokinin B receptor decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CCKBR mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:159,771,733...159,781,738
Ensembl chr 1:159,771,733...159,814,881
JBrowse link
G Ccn1 cellular communication network factor 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CCN1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
JBrowse link
G Ccn2 cellular communication network factor 2 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN2 mRNA CTD PMID:27188386 NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
JBrowse link
G Ccng2 cyclin G2 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CCNG2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNG2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830
JBrowse link
G Cd40 CD40 molecule decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CD40 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CD40 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
JBrowse link
G Cd44 CD44 molecule (Indian blood group) multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD44 mRNA CTD PMID:27188386 NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
JBrowse link
G Cd82 Cd82 molecule decreases expression ISO mercuric bromide results in decreased expression of CD82 mRNA CTD PMID:26272509 NCBI chr 3:79,387,361...79,431,847
Ensembl chr 3:79,385,887...79,431,809
JBrowse link
G Cd9 CD9 molecule increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CD9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD9 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:158,256,328...158,289,136
Ensembl chr 4:158,256,328...158,289,222
JBrowse link
G Cdc14b cell division cycle 14B multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDC14B mRNA CTD PMID:27188386 NCBI chr17:844,731...934,787
Ensembl chr17:844,685...933,235
JBrowse link
G Cdh1 cadherin 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CDH1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
JBrowse link
G Cdh10 cadherin 10 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CDH10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH10 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:68,628,623...68,850,995
Ensembl chr 2:68,628,780...68,850,995
JBrowse link
G Cdh13 cadherin 13 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CDH13 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH13 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:46,349,562...47,387,462
Ensembl chr19:46,349,430...47,387,459
JBrowse link
G Cdh3 cadherin 3 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CDH3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:34,393,596...34,444,084
Ensembl chr19:34,393,727...34,444,084
JBrowse link
G Cdh6 cadherin 6 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CDH6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:62,079,139...62,225,228
Ensembl chr 2:62,079,137...62,225,228
JBrowse link
G Cdh7 cadherin 7 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CDH7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH7 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:26,672,058...26,821,571
Ensembl chr13:26,672,484...26,819,846
JBrowse link
G Cdh9 cadherin 9 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CDH9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH9 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:66,280,422...66,367,121
Ensembl chr 2:66,228,117...66,367,121
JBrowse link
G Cdk19 cyclin-dependent kinase 19 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CDK19 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDK19 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr20:43,770,409...43,910,629
Ensembl chr20:43,770,409...43,910,628
JBrowse link
G Cdk6 cyclin-dependent kinase 6 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CDK6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDK6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CDKN1A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDKN1A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
JBrowse link
G Cdkn2a cyclin-dependent kinase inhibitor 2A increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CDKN2A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDKN2A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
JBrowse link
G Cds1 CDP-diacylglycerol synthase 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CDS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDS1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:7,820,328...7,882,943
Ensembl chr14:7,820,351...7,882,681
JBrowse link
G Cebpb CCAAT/enhancer binding protein beta increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CEBPB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPB mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
JBrowse link
G Cebpd CCAAT/enhancer binding protein delta multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPD mRNA CTD PMID:27188386 NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
JBrowse link
G Celf5 CUGBP, Elav-like family member 5 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CELF5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CELF5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:8,225,787...8,250,322
Ensembl chr 7:8,225,825...8,250,322
JBrowse link
G Cep85l centrosomal protein 85-like increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CEP85L mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr20:32,568,417...32,739,449
Ensembl chr20:32,572,741...32,739,516
JBrowse link
G Cfap300 cilia and flagella associated protein 300 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CFAP300 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP300 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:5,180,180...5,198,840
Ensembl chr 8:5,180,675...5,198,807
JBrowse link
G Cfap91 cilia and flagella associated protein 91 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CFAP91 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP91 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:62,413,613...62,457,281
Ensembl chr11:62,413,602...62,457,293
JBrowse link
G Cftr CF transmembrane conductance regulator increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CFTR mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CFTR mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
JBrowse link
G Chac1 ChaC glutathione-specific gamma-glutamylcyclotransferase 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHAC1 mRNA CTD PMID:27188386 NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526
JBrowse link
G Chka choline kinase alpha increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CHKA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHKA mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:201,076,804...201,125,517
Ensembl chr 1:201,076,860...201,125,516
JBrowse link
G Chmp4c charged multivesicular body protein 4C increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CHMP4C mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHMP4C mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:91,391,729...91,428,652
Ensembl chr 2:91,388,530...91,428,668
JBrowse link
G Chodl chondrolectin increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CHODL mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:17,654,137...17,676,450
Ensembl chr11:17,654,206...17,676,441
JBrowse link
G Chordc1 cysteine and histidine rich domain containing 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHORDC1 mRNA CTD PMID:27188386 NCBI chr 8:15,374,356...15,398,436
Ensembl chr 8:15,374,471...15,399,162
JBrowse link
G Chrdl1 chordin-like 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CHRDL1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CHRDL1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:106,889,125...106,992,937
Ensembl chr  X:106,889,125...106,992,921
JBrowse link
G Cldn11 claudin 11 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CLDN11 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN11 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:112,207,745...112,221,050
Ensembl chr 2:112,207,745...112,221,050
JBrowse link
G Cldn18 claudin 18 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN18 mRNA CTD PMID:27188386 NCBI chr 8:100,246,499...100,265,797
Ensembl chr 8:100,247,633...100,273,351
JBrowse link
G Cldn4 claudin 4 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CLDN4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:21,751,638...21,753,436
Ensembl chr12:21,751,331...21,753,436
JBrowse link
G Cldn7 claudin 7 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CLDN7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN7 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:54,689,684...54,692,177
Ensembl chr10:54,689,987...54,692,171
JBrowse link
G Clec18a C-type lectin domain family 18, member A decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CLEC18A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLEC18A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:39,038,498...39,053,425
Ensembl chr19:39,038,273...39,056,017
JBrowse link
G Cln8 CLN8, transmembrane ER and ERGIC protein increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CLN8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLN8 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:74,749,662...74,759,553
Ensembl chr16:74,749,662...74,759,774
JBrowse link
G Cnfn cornifelin decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CNFN mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNFN mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:80,949,699...80,953,747
Ensembl chr 1:80,951,600...80,953,747
JBrowse link
G Cnksr2 connector enhancer of kinase suppressor of Ras 2 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CNKSR2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:36,908,135...37,148,337
Ensembl chr  X:36,907,850...37,150,555
JBrowse link
G Cnot4 CCR4-NOT transcription complex, subunit 4 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CNOT4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNOT4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:63,712,770...63,814,355
Ensembl chr 4:63,712,770...63,814,360
JBrowse link
G Cntn2 contactin 2 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CNTN2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:43,942,868...43,975,973
Ensembl chr13:43,947,265...43,975,887
JBrowse link
G Cntnap3 contactin associated protein family member 3 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CNTNAP3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTNAP3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:267,238...455,372
Ensembl chr17:267,508...454,102
JBrowse link
G Col11a1 collagen type XI alpha 1 chain increases expression
multiple interactions
ISO mercuric bromide results in increased expression of COL11A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL11A1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853
JBrowse link
G Col12a1 collagen type XII alpha 1 chain increases expression
multiple interactions
ISO mercuric bromide results in increased expression of COL12A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL12A1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:80,547,592...80,665,665
Ensembl chr 8:80,547,593...80,665,686
JBrowse link
G Col1a1 collagen type I alpha 1 chain increases expression
multiple interactions
ISO mercuric bromide results in increased expression of COL1A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
JBrowse link
G Col1a2 collagen type I alpha 2 chain increases expression
multiple interactions
ISO mercuric bromide results in increased expression of COL1A2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
JBrowse link
G Col3a1 collagen type III alpha 1 chain multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL3A1 mRNA CTD PMID:27188386 NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
JBrowse link
G Col6a3 collagen type VI alpha 3 chain multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A3 mRNA CTD PMID:27188386 NCBI chr 9:91,361,578...91,439,434
Ensembl chr 9:91,361,583...91,439,471
JBrowse link
G Col8a1 collagen type VIII alpha 1 chain multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL8A1 mRNA CTD PMID:27188386 NCBI chr11:42,776,851...42,906,432
Ensembl chr11:42,777,628...42,906,424
JBrowse link
G Colgalt2 collagen beta(1-O)galactosyltransferase 2 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of COLGALT2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:64,523,641...64,628,295
Ensembl chr13:64,523,658...64,627,549
JBrowse link
G Cops8 COP9 signalosome subunit 8 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of COPS8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COPS8 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:91,207,427...91,217,258
Ensembl chr 9:91,207,395...91,217,258
JBrowse link
G Cpe carboxypeptidase E increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CPE mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPE mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:25,030,276...25,142,231
Ensembl chr16:25,030,276...25,142,233
JBrowse link
G Cpeb2 cytoplasmic polyadenylation element binding protein 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CPEB2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPEB2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:67,787,503...67,839,973
Ensembl chr14:67,787,507...67,840,743
JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CPT1A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPT1A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
JBrowse link
G Cpxm2 carboxypeptidase X (M14 family), member 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CPXM2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPXM2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:186,836,797...186,947,222
Ensembl chr 1:186,836,797...186,947,220
JBrowse link
G Creg1 cellular repressor of E1A-stimulated genes 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CREG1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CREG1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:78,019,814...78,032,310
Ensembl chr13:78,019,843...78,032,308
JBrowse link
G Crim1 cysteine rich transmembrane BMP regulator 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CRIM1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIM1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:16,695,864...16,870,264
Ensembl chr 6:16,697,829...16,870,259
JBrowse link
G Cryba4 crystallin, beta A4 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CRYBA4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:44,378,734...44,393,226
Ensembl chr12:44,378,737...44,393,221
JBrowse link
G Csf2ra colony stimulating factor 2 receptor subunit alpha increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CSF2RA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSF2RA mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:98,089...103,261
Ensembl chr14:89,172...103,128
JBrowse link
G Cspg5 chondroitin sulfate proteoglycan 5 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CSPG5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSPG5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:110,220,653...110,234,750
Ensembl chr 8:110,220,653...110,234,758
JBrowse link
G Csrp1 cysteine and glycine-rich protein 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSRP1 mRNA CTD PMID:27188386 NCBI chr13:47,158,171...47,179,388
Ensembl chr13:47,167,789...47,179,384
JBrowse link
G Ctdsp1 CTD small phosphatase 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CTDSP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTDSP1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:75,973,694...75,979,298
Ensembl chr 9:75,973,962...75,979,297
JBrowse link
G Cth cystathionine gamma-lyase increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CTH mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTH mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234
JBrowse link
G Cthrc1 collagen triple helix repeat containing 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CTHRC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTHRC1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:70,122,474...70,132,756
Ensembl chr 7:70,122,474...70,132,756
JBrowse link
G Ctnnd2 catenin delta 2 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CTNND2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:81,168,976...82,016,495
Ensembl chr 2:81,167,117...82,015,764
JBrowse link
G Cul3 cullin 3 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUL3 mRNA CTD PMID:27188386 NCBI chr 9:81,592,641...81,670,428
Ensembl chr 9:81,592,641...81,670,462
JBrowse link
G Cxcl14 C-X-C motif chemokine ligand 14 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CXCL14 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL14 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:8,317,933...8,325,956
Ensembl chr17:8,317,933...8,324,839
JBrowse link
G Cxcr4 C-X-C motif chemokine receptor 4 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of CXCR4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CXCR4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
JBrowse link
G Cyb5a cytochrome b5 type A increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CYB5A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYB5A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535
Ensembl chr18:78,202,342...78,258,535
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CYP1A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1A1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CYP1B1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1B1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
JBrowse link
G Cyth3 cytohesin 3 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of CYTH3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYTH3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:10,840,137...10,933,792
Ensembl chr12:10,840,157...10,933,812
JBrowse link
G Dab1 DAB adaptor protein 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of DAB1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAB1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:118,392,953...119,513,625
Ensembl chr 5:119,140,533...119,510,552
JBrowse link
G Dclk2 doublecortin-like kinase 2 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of DCLK2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCLK2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:172,202,733...172,338,411
Ensembl chr 2:172,208,706...172,338,250
JBrowse link
G Dcx doublecortin decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of DCX mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCX mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:107,430,767...107,573,612
Ensembl chr  X:107,430,767...107,507,476
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DDIT3 mRNA CTD PMID:27188386 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
JBrowse link
G Ddr2 discoidin domain receptor tyrosine kinase 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of DDR2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DDR2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:82,193,623...82,318,229
Ensembl chr13:82,195,463...82,317,363
JBrowse link
G Dennd1b DENN domain containing 1B decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of DENND1B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1B mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:50,545,324...50,772,922
Ensembl chr13:50,545,836...50,770,601
JBrowse link
G Dgki diacylglycerol kinase, iota decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of DGKI mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:65,410,878...65,872,733
Ensembl chr 4:65,420,108...65,872,733
JBrowse link
G Dhrs11 dehydrogenase/reductase 11 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of DHRS11 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DHRS11 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:69,698,214...69,708,294
Ensembl chr10:69,698,214...69,708,295
JBrowse link
G Dhx15 DEAH-box helicase 15 decreases expression ISO mercuric bromide results in decreased expression of DHX15 mRNA CTD PMID:26272509 NCBI chr14:58,787,147...58,825,083
Ensembl chr14:58,787,127...58,825,088
JBrowse link
G Dipk1c divergent protein kinase domain 1C decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of DIPK1C mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIPK1C mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:78,087,972...78,109,910
Ensembl chr18:78,087,991...78,109,904
JBrowse link
G Dlc1 DLC1 Rho GTPase activating protein increases expression
multiple interactions
ISO mercuric bromide results in increased expression of DLC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLC1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:55,246,716...55,671,441
Ensembl chr16:55,291,584...55,671,439
JBrowse link
G Dll1 delta like canonical Notch ligand 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of DLL1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:56,312,062...56,320,177
Ensembl chr 1:56,312,066...56,320,179
JBrowse link
G Dlx3 distal-less homeobox 3 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of DLX3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:80,064,489...80,069,891
Ensembl chr10:80,064,489...80,069,872
JBrowse link
G Dlx5 distal-less homeobox 5 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of DLX5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:34,999,139...35,003,504
Ensembl chr 4:34,999,139...35,003,407
JBrowse link
G Dlx6 distal-less homeobox 6 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of DLX6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:34,984,264...34,989,926
Ensembl chr 4:34,984,232...34,991,343
JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNAJB1 mRNA CTD PMID:27188386 NCBI chr19:24,522,717...24,526,458
Ensembl chr19:24,522,717...24,526,458
JBrowse link
G Dnajc6 DnaJ heat shock protein family (Hsp40) member C6 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of DNAJC6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNAJC6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:116,120,069...116,283,448
Ensembl chr 5:116,119,676...116,283,448
JBrowse link
G Dock6 dedicator of cytokinesis 6 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of DOCK6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DOCK6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:20,342,089...20,394,660
Ensembl chr 8:20,342,089...20,394,552
JBrowse link
G Dock7 dedicator of cytokinesis 7 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of DOCK7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DOCK7 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:113,599,371...113,782,871
Ensembl chr 5:113,600,198...113,782,813
JBrowse link
G Dock8 dedicator of cytokinesis 8 decreases expression ISO mercuric bromide results in decreased expression of DOCK8 mRNA CTD PMID:26272509 NCBI chr 1:222,649,309...222,842,474
Ensembl chr 1:222,649,309...222,842,474
JBrowse link
G Dock9 dedicator of cytokinesis 9 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of DOCK9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK9 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:98,611,518...98,883,306
Ensembl chr15:98,618,084...98,883,153
JBrowse link
G Dqx1 DEAQ box RNA-dependent ATPase 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DQX1 mRNA CTD PMID:27188386 NCBI chr 4:115,563,497...115,572,598
Ensembl chr 4:115,563,752...115,572,590
JBrowse link
G Drd4 dopamine receptor D4 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of DRD4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DRD4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553
JBrowse link
G Dsc3 desmocollin 3 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of DSC3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DSC3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:11,379,759...11,413,797
Ensembl chr18:11,377,347...11,413,797
JBrowse link
G Dsp desmoplakin increases expression
multiple interactions
ISO mercuric bromide results in increased expression of DSP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DSP mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:26,623,602...26,671,692
Ensembl chr17:26,623,588...26,671,800
JBrowse link
G Dstyk dual serine/threonine and tyrosine protein kinase decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of DSTYK mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DSTYK mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:43,857,266...43,905,280
Ensembl chr13:43,857,266...43,905,269
JBrowse link
G Dtna dystrobrevin, alpha increases expression
multiple interactions
ISO mercuric bromide results in increased expression of DTNA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DTNA mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:14,687,193...14,944,232
Ensembl chr18:14,587,852...14,944,261
JBrowse link
G Dusp1 dual specificity phosphatase 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP1 mRNA CTD PMID:27188386 NCBI chr10:16,680,489...16,683,276 JBrowse link
G Dusp10 dual specificity phosphatase 10 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP10 mRNA CTD PMID:27188386 NCBI chr13:95,613,716...95,651,716
Ensembl chr13:95,614,292...95,651,716
JBrowse link
G Dusp14 dual specificity phosphatase 14 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of DUSP14 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP14 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:68,936,483...68,966,347
Ensembl chr10:68,935,330...68,965,329
JBrowse link
G Dusp2 dual specificity phosphatase 2 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP2 mRNA CTD PMID:27188386 NCBI chr 3:114,556,325...114,558,510
Ensembl chr 3:114,556,325...114,558,499
JBrowse link
G Dusp5 dual specificity phosphatase 5 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of DUSP5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818
JBrowse link
G Dusp8 dual specificity phosphatase 8 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP8 mRNA CTD PMID:27188386 NCBI chr 1:197,167,392...197,184,285
Ensembl chr 1:197,169,422...197,182,921
JBrowse link
G Eaf2 ELL associated factor 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of EAF2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EAF2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:63,960,200...64,004,610
Ensembl chr11:63,960,200...64,004,610
JBrowse link
G Ebf1 EBF transcription factor 1 decreases expression ISO mercuric bromide results in decreased expression of EBF1 mRNA CTD PMID:26272509 NCBI chr10:29,095,858...29,489,142
Ensembl chr10:29,099,933...29,487,665
JBrowse link
G Edn1 endothelin 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDN1 mRNA CTD PMID:27188386 NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
JBrowse link
G Ednrb endothelin receptor type B increases expression ISO mercuric bromide results in increased expression of EDNRB mRNA CTD PMID:26272509 NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
JBrowse link
G Eef1akmt2 EEF1A lysine methyltransferase 2 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of EEF1AKMT2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EEF1AKMT2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:187,616,156...187,640,937
Ensembl chr 1:187,500,744...187,640,937
JBrowse link
G Efhc2 EF-hand domain containing 2 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFHC2 mRNA CTD PMID:27188386 NCBI chr  X:5,360,499...5,564,004
Ensembl chr  X:5,360,617...5,560,970
JBrowse link
G Efna1 ephrin A1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA CTD PMID:27188386 NCBI chr 2:174,681,676...174,690,306
Ensembl chr 2:174,681,682...174,690,866
JBrowse link
G Efna2 ephrin A2 decreases expression ISO mercuric bromide results in decreased expression of EFNA2 mRNA CTD PMID:26272509 NCBI chr 7:9,515,635...9,528,071
Ensembl chr 7:9,516,429...9,527,061
JBrowse link
G Egf epidermal growth factor multiple interactions
increases expression
ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGF mRNA
mercuric bromide results in increased expression of EGF mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
JBrowse link
G Egfl7 EGF-like-domain, multiple 7 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of EGFL7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGFL7 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:9,404,622...9,416,879
Ensembl chr 3:9,407,520...9,416,879
JBrowse link
G Eid3 EP300 interacting inhibitor of differentiation 3 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of EID3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EID3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:20,860,073...20,861,395 JBrowse link
G Eif4e3 eukaryotic translation initiation factor 4E family member 3 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of EIF4E3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF4E3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:132,258,502...132,301,808
Ensembl chr 4:132,258,502...132,301,808
JBrowse link
G Elf3 E74 like ETS transcription factor 3 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF3 mRNA CTD PMID:27188386 NCBI chr13:46,690,460...46,695,394
Ensembl chr13:46,690,466...46,695,481
JBrowse link
G Elf4 E74 like ETS transcription factor 4 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ELF4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:127,587,401...127,639,063
Ensembl chr  X:127,590,650...127,630,200
JBrowse link
G Elf5 E74 like ETS transcription factor 5 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ELF5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:89,808,836...89,836,977
Ensembl chr 3:89,797,880...89,836,973
JBrowse link
G Elk3 ETS transcription factor ELK3 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ELK3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELK3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:27,768,582...27,831,088
Ensembl chr 7:27,768,599...27,804,084
JBrowse link
G Elmod1 ELMO domain containing 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ELMOD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELMOD1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:54,298,363...54,355,348
Ensembl chr 8:54,298,363...54,355,140
JBrowse link
G Emp1 epithelial membrane protein 1 increases expression ISO mercuric bromide results in increased expression of EMP1 mRNA CTD PMID:26272509 NCBI chr 4:168,212,901...168,233,039
Ensembl chr 4:168,212,861...168,232,904
JBrowse link
G Ensa endosulfine alpha increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ENSA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENSA mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:183,185,552...183,192,888
Ensembl chr 2:183,185,552...183,194,847
JBrowse link
G Eogt EGF domain specific O-linked N-acetylglucosamine transferase increases expression
multiple interactions
ISO mercuric bromide results in increased expression of EOGT mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EOGT mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:129,718,897...129,756,558
Ensembl chr 4:129,718,901...129,756,445
JBrowse link
G Epas1 endothelial PAS domain protein 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of EPAS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPAS1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:7,790,236...7,871,246
Ensembl chr 6:7,790,647...7,871,228
JBrowse link
G Epb41l3 erythrocyte membrane protein band 4.1-like 3 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA CTD PMID:27188386 NCBI chr 9:109,056,178...109,260,607
Ensembl chr 9:109,016,113...109,260,607
JBrowse link
G Epb41l5 erythrocyte membrane protein band 4.1 like 5 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of EPB41L5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:30,673,052...30,770,213
Ensembl chr13:30,669,764...30,768,360
JBrowse link
G Epcam epithelial cell adhesion molecule increases expression
multiple interactions
ISO mercuric bromide results in increased expression of EPCAM mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPCAM mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:6,880,142...6,896,103
Ensembl chr 6:6,878,237...6,896,127
JBrowse link
G Epdr1 ependymin related 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of EPDR1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPDR1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:45,333,677...45,358,597
Ensembl chr17:45,333,956...45,358,594
JBrowse link
G Epha2 Eph receptor A2 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA2 mRNA CTD PMID:27188386 NCBI chr 5:153,605,644...153,634,115
Ensembl chr 5:153,605,644...153,634,117
JBrowse link
G Ephb1 Eph receptor B1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of EPHB1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:102,507,549...102,944,839
Ensembl chr 8:102,507,549...102,944,839
JBrowse link
G Ephb2 Eph receptor B2 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of EPHB2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:148,889,574...149,077,027
Ensembl chr 5:148,897,246...149,077,059
JBrowse link
G Epn3 epsin 3 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of EPN3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPN3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:79,438,978...79,449,516
Ensembl chr10:79,438,978...79,447,356
JBrowse link
G Eps8l2 EPS8-like 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of EPS8L2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPS8L2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:196,446,067...196,471,542
Ensembl chr 1:196,446,287...196,471,541
JBrowse link
G Epsti1 epithelial stromal interaction 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of EPSTI1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPSTI1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:53,283,964...53,382,192
Ensembl chr15:53,284,216...53,382,191
JBrowse link
G Erap1 endoplasmic reticulum aminopeptidase 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of ERAP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERAP1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:3,931,817...3,970,735
Ensembl chr 2:3,931,904...3,972,447
JBrowse link
G Erich1 glutamate-rich 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of ERICH1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERICH1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:75,501,322...75,569,129
Ensembl chr16:75,501,384...75,569,128
JBrowse link
G Erich5 glutamate-rich 5 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ERICH5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERICH5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:65,655,829...65,682,221
Ensembl chr 7:65,657,204...65,680,207
JBrowse link
G Ero1b endoplasmic reticulum oxidoreductase 1 beta multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERO1B mRNA CTD PMID:27188386 NCBI chr17:85,861,086...86,003,244
Ensembl chr17:85,929,618...86,003,398
JBrowse link
G Erp27 endoplasmic reticulum protein 27 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ERP27 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERP27 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:169,804,656...169,821,660
Ensembl chr 4:169,804,658...169,821,660
JBrowse link
G Esrp1 epithelial splicing regulatory protein 1 increases expression ISO mercuric bromide results in increased expression of ESRP1 mRNA CTD PMID:26272509 NCBI chr 5:24,427,611...24,482,157
Ensembl chr 5:24,428,717...24,482,062
JBrowse link
G Esrp2 epithelial splicing regulatory protein 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ESRP2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:34,034,559...34,041,726
Ensembl chr19:34,034,559...34,041,726
JBrowse link
G Etl4 enhancer trap locus 4 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of KIAA1217 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA1217 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:82,841,075...83,304,868
Ensembl chr17:82,495,041...83,304,715
JBrowse link
G Etnk1 ethanolamine kinase 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ETNK1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETNK1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:176,126,056...176,170,325
Ensembl chr 4:176,126,180...176,193,770
JBrowse link
G Ets1 ETS proto-oncogene 1, transcription factor increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ETS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETS1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:31,045,909...31,168,010
Ensembl chr 8:31,045,945...31,168,010
JBrowse link
G Evc2 EvC ciliary complex subunit 2 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EVC2 mRNA CTD PMID:27188386 NCBI chr14:73,366,832...73,454,539
Ensembl chr14:73,367,963...73,454,516
JBrowse link
G F2rl2 coagulation factor II (thrombin) receptor-like 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of F2RL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:26,972,054...26,977,098
Ensembl chr 2:26,972,054...26,977,098
JBrowse link
G F3 coagulation factor III, tissue factor increases expression
multiple interactions
ISO mercuric bromide results in increased expression of F3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
JBrowse link
G F5 coagulation factor V increases expression
multiple interactions
ISO mercuric bromide results in increased expression of F5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:76,513,463...76,583,106
Ensembl chr13:76,513,255...76,582,317
JBrowse link
G Fam110c family with sequence similarity 110, member C increases expression
multiple interactions
ISO mercuric bromide results in increased expression of FAM110C mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM110C mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:47,638,466...47,644,723
Ensembl chr 6:47,638,276...47,644,634
JBrowse link
G Fam124a family with sequence similarity 124 member A decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of FAM124A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM124A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:36,799,836...36,855,062
Ensembl chr15:36,799,877...36,853,683
JBrowse link
G Fam13c family with sequence similarity 13, member C increases expression
multiple interactions
ISO mercuric bromide results in increased expression of FAM13C mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM13C mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr20:18,065,625...18,187,653
Ensembl chr20:18,065,628...18,187,592
JBrowse link
G Fam149a family with sequence similarity 149, member A decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of FAM149A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM149A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:46,855,377...46,914,553
Ensembl chr16:46,854,635...46,912,066
JBrowse link
G Fam169a family with sequence similarity 169, member A increases expression
multiple interactions
ISO mercuric bromide results in increased expression of FAM169A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM169A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:28,384,162...28,441,361
Ensembl chr 2:28,383,784...28,438,910
JBrowse link
G Fam222a family with sequence similarity 222, member A decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of FAM222A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM222A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:41,982,064...42,033,085
Ensembl chr12:41,986,780...42,033,682
JBrowse link
G Fam241a family with sequence similarity 241 member A multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM241A mRNA CTD PMID:27188386 NCBI chr 2:216,344,563...216,375,193
Ensembl chr 2:216,343,822...216,375,242
JBrowse link
G Fam89a family with sequence similarity 89, member A increases expression
multiple interactions
ISO mercuric bromide results in increased expression of FAM89A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM89A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:52,710,003...52,722,591
Ensembl chr19:52,710,019...52,722,631
JBrowse link
G Fas Fas cell surface death receptor increases expression
multiple interactions
ISO mercuric bromide results in increased expression of FAS mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAS mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
JBrowse link
G Fblim1 filamin binding LIM protein 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBLIM1 mRNA CTD PMID:27188386 NCBI chr 5:153,883,946...153,915,524
Ensembl chr 5:153,883,960...153,913,757
JBrowse link
G Fbxo9 f-box protein 9 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of FBXO9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO9 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:78,958,482...78,984,015
Ensembl chr 8:78,958,483...78,983,949
JBrowse link
G Fech ferrochelatase increases expression
multiple interactions
ISO mercuric bromide results in increased expression of FECH mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FECH mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348
JBrowse link
G Fez1 fasciculation and elongation protein zeta 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of FEZ1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZ1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:36,544,462...36,589,684
Ensembl chr 8:36,544,535...36,589,683
JBrowse link
G Fezf2 Fez family zinc finger 2 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of FEZF2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:12,768,614...12,777,554
Ensembl chr15:12,773,762...12,777,554
JBrowse link
G Fgb fibrinogen beta chain increases expression
multiple interactions
ISO mercuric bromide results in increased expression of FGB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGB mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979
JBrowse link
G Fgf9 fibroblast growth factor 9 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA CTD PMID:27188386 NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309
JBrowse link
G Fgfr2 fibroblast growth factor receptor 2 decreases expression ISO mercuric bromide results in decreased expression of FGFR2 mRNA CTD PMID:26272509 NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626
JBrowse link
G Fhod3 formin homology 2 domain containing 3 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of FHOD3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FHOD3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:15,993,079...16,425,796
Ensembl chr18:15,993,324...16,425,796
JBrowse link
G Fjx1 four-jointed box kinase 1 decreases expression ISO mercuric bromide results in decreased expression of FJX1 mRNA CTD PMID:26272509 NCBI chr 3:88,774,220...88,776,321
Ensembl chr 3:88,774,220...88,776,321
JBrowse link
G Fkbp5 FKBP prolyl isomerase 5 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of FKBP5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FKBP5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674
JBrowse link
G Fli1 Fli-1 proto-oncogene, ETS transcription factor multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLI1 mRNA CTD PMID:27188386 NCBI chr 8:30,831,422...30,950,468
Ensembl chr 8:30,832,753...30,950,433
JBrowse link
G Flnb filamin B increases expression
multiple interactions
ISO mercuric bromide results in increased expression of FLNB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLNB mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:16,961,999...17,095,059
Ensembl chr15:16,962,003...17,095,006
JBrowse link
G Flnc filamin C increases expression ISO mercuric bromide results in increased expression of FLNC mRNA CTD PMID:26272509 NCBI chr 4:58,034,088...58,061,882
Ensembl chr 4:58,034,189...58,061,844
JBrowse link
G Flt1 Fms related receptor tyrosine kinase 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of FLT1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLT1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
JBrowse link
G Fn1 fibronectin 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of FN1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FN1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
JBrowse link
G Fndc4 fibronectin type III domain containing 4 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of FNDC4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:25,077,155...25,080,812
Ensembl chr 6:25,077,349...25,080,675
JBrowse link
G Fndc5 fibronectin type III domain containing 5 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of FNDC5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:141,481,593...141,491,257
Ensembl chr 5:141,481,590...141,490,731
JBrowse link
G Fosl1 FOS like 1, AP-1 transcription factor subunit increases expression
multiple interactions
ISO mercuric bromide results in increased expression of FOSL1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOSL1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
JBrowse link
G Fosl2 FOS like 2, AP-1 transcription factor subunit increases expression
multiple interactions
ISO mercuric bromide results in increased expression of FOSL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOSL2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:24,297,898...24,319,157
Ensembl chr 6:24,300,956...24,320,034
JBrowse link
G Foxc1 forkhead box C1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of FOXC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:32,631,379...32,635,361
Ensembl chr17:32,633,142...32,634,803
JBrowse link
G Foxc2 forkhead box C2 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC2 mRNA CTD PMID:27188386 NCBI chr19:49,186,034...49,188,736
Ensembl chr19:49,185,662...49,188,737
JBrowse link
G Foxl2 forkhead box L2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of FOXL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXL2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:99,512,971...99,514,500
Ensembl chr 8:99,513,303...99,514,427
JBrowse link
G Frem1 Fras1 related extracellular matrix 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of FREM1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FREM1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:97,321,275...97,469,523
Ensembl chr 5:97,322,538...97,469,543
JBrowse link
G Frmd3 FERM domain containing 3 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of FRMD3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRMD3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:87,764,604...88,032,261
Ensembl chr 5:87,764,604...88,031,091
JBrowse link
G Frzb frizzled-related protein multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRZB mRNA CTD PMID:27188386 NCBI chr 3:65,332,274...65,365,208
Ensembl chr 3:65,332,277...65,365,208
JBrowse link
G Fth1 ferritin heavy chain 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of FTH1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FTH1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
JBrowse link
G Ftl1 ferritin light chain 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of FTL mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FTL mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:95,936,390...95,938,234
Ensembl chr 1:95,936,387...95,939,725
Ensembl chr10:95,936,387...95,939,725
JBrowse link
G Ftx FTX transcript, XIST regulator increases expression ISO mercuric bromide results in increased expression of FTX mRNA CTD PMID:26272509 NCBI chr  X:68,588,349...68,630,338 JBrowse link
G Fzd10 frizzled class receptor 10 decreases expression ISO mercuric bromide results in decreased expression of FZD10 mRNA CTD PMID:26272509 NCBI chr12:28,098,371...28,101,566
Ensembl chr12:28,098,371...28,101,566
JBrowse link
G Gabarapl1 GABA type A receptor associated protein like 1 increases expression ISO mercuric bromide results in increased expression of GABARAPL1 mRNA CTD PMID:26272509 NCBI chr 4:162,980,309...162,989,452
Ensembl chr 4:162,980,249...162,989,450
JBrowse link
G Gabra5 gamma-aminobutyric acid type A receptor subunit alpha 5 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of GABRA5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GABRA5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:108,268,728...108,381,670
Ensembl chr 1:108,268,776...108,380,917
JBrowse link
G Gabrb2 gamma-aminobutyric acid type A receptor subunit beta 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of GABRB2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:26,936,592...27,156,141
Ensembl chr10:26,936,551...27,151,251
JBrowse link
G Gabrb3 gamma-aminobutyric acid type A receptor subunit beta 3 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of GABRB3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:108,467,047...108,702,522
Ensembl chr 1:108,296,124...108,698,961
JBrowse link
G Gabrp gamma-aminobutyric acid type A receptor subunit pi increases expression
multiple interactions
ISO mercuric bromide results in increased expression of GABRP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRP mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:18,143,031...18,169,595
Ensembl chr10:18,143,038...18,169,516
JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha increases expression
multiple interactions
ISO mercuric bromide results in increased expression of GADD45A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
JBrowse link
G Gadd45b growth arrest and DNA-damage-inducible, beta multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45B mRNA CTD PMID:27188386 NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
JBrowse link
G Gal galanin and GMAP prepropeptide decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of GAL mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAL mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959
JBrowse link
G Galnt10 polypeptide N-acetylgalactosaminyltransferase 10 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of GALNT10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALNT10 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:41,821,216...41,967,618
Ensembl chr10:41,820,158...41,967,013
JBrowse link
G Galnt14 polypeptide N-acetylgalactosaminyltransferase 14 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of GALNT14 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALNT14 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:21,756,039...21,977,533
Ensembl chr 6:21,755,195...21,972,192
JBrowse link
G Galnt3 polypeptide N-acetylgalactosaminyltransferase 3 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of GALNT3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:50,742,500...50,779,266
Ensembl chr 3:50,742,512...50,766,268
JBrowse link
G Galp galanin-like peptide decreases expression ISO mercuric bromide results in decreased expression of GALP mRNA CTD PMID:26272509 NCBI chr 1:67,684,023...67,703,121
Ensembl chr 1:67,684,025...67,702,269
JBrowse link
G Gas1 growth arrest-specific 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of GAS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAS1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:4,482,014...4,485,155 JBrowse link
G Gas2l1 growth arrest-specific 2 like 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of GAS2L1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAS2L1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:79,951,702...79,961,830
Ensembl chr14:79,950,555...79,961,438
JBrowse link
G Gask1b golgi associated kinase 1B multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GASK1B mRNA CTD PMID:27188386 NCBI chr 2:165,047,689...165,112,479
Ensembl chr 2:165,047,684...165,112,477
JBrowse link
G Gata2 GATA binding protein 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of GATA2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:120,654,205...120,667,763
Ensembl chr 4:120,658,986...120,667,761
JBrowse link
G Gata3 GATA binding protein 3 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of GATA3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391
JBrowse link
G Gata6 GATA binding protein 6 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of GATA6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:2,188,121...2,219,532
Ensembl chr18:2,188,121...2,219,532
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit increases expression
multiple interactions
ISO mercuric bromide results in increased expression of GCLC mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCLC mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit increases expression
multiple interactions
ISO mercuric bromide results in increased expression of GCLM mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCLM mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
JBrowse link
G Gcnt1 glucosaminyl (N-acetyl) transferase 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of GCNT1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GCNT1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:214,718,344...214,755,735
Ensembl chr 1:214,718,293...214,758,776
JBrowse link
G Gdap1l1 ganglioside-induced differentiation-associated protein 1-like 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GDAP1L1 mRNA CTD PMID:27188386 NCBI chr 3:152,110,225...152,129,693
Ensembl chr 3:152,110,253...152,128,711
JBrowse link
G Gdf15 growth differentiation factor 15 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of GDF15 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDF15 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:18,805,312...18,807,893
Ensembl chr16:18,805,239...18,808,055
JBrowse link
G Gjb2 gap junction protein, beta 2 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJB2 mRNA CTD PMID:27188386 NCBI chr15:31,260,390...31,278,222
Ensembl chr15:31,260,357...31,278,177
JBrowse link
G Glipr1 GLI pathogenesis-related 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLIPR1 mRNA CTD PMID:27188386 NCBI chr 7:47,487,342...47,498,974
Ensembl chr 7:47,487,345...47,498,429
JBrowse link
G Glis3 GLIS family zinc finger 3 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of GLIS3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:225,976,029...226,395,849
Ensembl chr 1:225,976,326...226,395,899
JBrowse link
G Glrx2 glutaredoxin 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of GLRX2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLRX2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:55,481,875...55,504,737
Ensembl chr13:55,482,694...55,492,831
JBrowse link
G Gls glutaminase increases expression
multiple interactions
ISO mercuric bromide results in increased expression of GLS mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLS mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900
JBrowse link
G Gna14 G protein subunit alpha 14 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of GNA14 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNA14 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:213,714,993...213,900,083
Ensembl chr 1:213,716,020...213,897,423
JBrowse link
G Gnas GNAS complex locus increases expression ISO mercuric bromide results in increased expression of GNAS mRNA CTD PMID:26272509 NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262
Ensembl chr 3:163,071,417...163,127,262
JBrowse link
G Gne glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of GNE mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNE mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:58,267,189...58,307,396
Ensembl chr 5:58,267,210...58,307,499
JBrowse link
G Gng11 G protein subunit gamma 11 increases expression ISO mercuric bromide results in increased expression of GNG11 mRNA CTD PMID:26272509 NCBI chr 4:32,023,003...32,028,443
Ensembl chr 4:32,023,003...32,028,442
JBrowse link
G Gng8 G protein subunit gamma 8 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of GNG8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNG8 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:77,564,512...77,568,371
Ensembl chr 1:77,564,515...77,568,371
JBrowse link
G Gpat3 glycerol-3-phosphate acyltransferase 3 multiple interactions
increases expression
ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPAT3 mRNA
mercuric bromide results in increased expression of GPAT3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:8,715,367...8,768,051
Ensembl chr14:8,714,373...8,766,490
JBrowse link
G Gpm6a glycoprotein m6a increases expression ISO mercuric bromide results in increased expression of GPM6A mRNA CTD PMID:26272509 NCBI chr16:36,641,282...36,973,477
Ensembl chr16:36,641,284...36,973,475
JBrowse link
G Gpm6b glycoprotein m6b decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of GPM6B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPM6B mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:28,057,788...28,204,409
Ensembl chr  X:28,059,450...28,204,211
JBrowse link
G Gpnmb glycoprotein nmb increases expression
multiple interactions
ISO mercuric bromide results in increased expression of GPNMB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPNMB mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367
JBrowse link
G Gpr153 G protein-coupled receptor 153 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of GPR153 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR153 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:162,781,587...162,792,975
Ensembl chr 5:162,781,587...162,792,971
JBrowse link
G Gpr27 G protein-coupled receptor 27 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of GPR27 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR27 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:132,328,364...132,329,497
Ensembl chr 4:132,328,364...132,329,497
JBrowse link
G Gpr37 G protein-coupled receptor 37 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of GPR37 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR37 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:54,138,860...54,160,927
Ensembl chr 4:54,138,870...54,161,001
JBrowse link
G Gpr39 G protein-coupled receptor 39 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of GPR39 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR39 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:37,115,258...37,327,312
Ensembl chr13:37,115,102...37,328,267
JBrowse link
G Gpr87 G protein-coupled receptor 87 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of GPR87 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR87 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:143,439,741...143,440,901
Ensembl chr 2:143,439,735...143,458,190
JBrowse link
G Gprc5a G protein-coupled receptor, class C, group 5, member A increases expression
multiple interactions
ISO mercuric bromide results in increased expression of GPRC5A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPRC5A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:167,903,542...167,922,276
Ensembl chr 4:167,903,542...167,922,260
JBrowse link
G Gpx3 glutathione peroxidase 3 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPX3 mRNA CTD PMID:27188386 NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035
JBrowse link
G Gramd1c GRAM domain containing 1C decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of GRAMD1C mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRAMD1C mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:56,633,229...56,718,570
Ensembl chr11:56,633,227...56,718,570
JBrowse link
G Grem1 gremlin 1, DAN family BMP antagonist increases expression
multiple interactions
ISO mercuric bromide results in increased expression of GREM1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:100,512,317...100,524,001
Ensembl chr 3:100,512,313...100,524,082
JBrowse link
G Grhl1 grainyhead-like transcription factor 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL1 mRNA CTD PMID:27188386 NCBI chr 6:41,207,325...41,257,516
Ensembl chr 6:41,207,348...41,254,301
JBrowse link
G Grhl2 grainyhead-like transcription factor 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of GRHL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:68,400,287...68,530,269
Ensembl chr 7:68,400,477...68,530,258
JBrowse link
G Grhl3 grainyhead-like transcription factor 3 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of GRHL3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:147,774,160...147,806,338
Ensembl chr 5:147,774,160...147,806,160
JBrowse link
G Gria3 glutamate ionotropic receptor AMPA type subunit 3 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of GRIA3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:120,238,515...120,504,106
Ensembl chr  X:120,238,534...120,504,096
JBrowse link
G Grin2a glutamate ionotropic receptor NMDA type subunit 2A decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of GRIN2A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIN2A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:5,630,684...6,043,341
Ensembl chr10:5,631,369...6,044,637
JBrowse link
G Gsr glutathione-disulfide reductase increases expression
multiple interactions
ISO mercuric bromide results in increased expression of GSR mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GSR mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
JBrowse link
G Gstm2 glutathione S-transferase mu 2 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of GSTM2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GSTM2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
JBrowse link
G Gstp1 glutathione S-transferase pi 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of GSTP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GSTP1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
JBrowse link
G Guca1a guanylate cyclase activator 1A multiple interactions
decreases expression
ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GUCA1A mRNA
mercuric bromide results in decreased expression of GUCA1A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:13,587,695...13,598,566
Ensembl chr 9:13,588,525...13,598,565
JBrowse link
G Gulp1 GULP PTB domain containing engulfment adaptor 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of GULP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GULP1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:46,622,699...46,899,005
Ensembl chr 9:46,622,669...46,899,005
JBrowse link
G Gxylt2 glucoside xylosyltransferase 2 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GXYLT2 mRNA CTD PMID:27188386 NCBI chr 4:133,347,230...133,449,708
Ensembl chr 4:133,347,499...133,449,454
JBrowse link
G H4f3 H1.3 linker histone, cluster member decreases expression ISO mercuric bromide results in decreased expression of H1-3 mRNA CTD PMID:26272509 NCBI chr17:41,528,576...41,554,586
Ensembl chr17:41,529,667...41,552,334
JBrowse link
G Hacd1 3-hydroxyacyl-CoA dehydratase 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of HACD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:77,081,508...77,106,114
Ensembl chr17:77,083,740...77,106,073
JBrowse link
G Hand1 heart and neural crest derivatives expressed 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAND1 mRNA CTD PMID:27188386 NCBI chr10:42,006,646...42,009,213
Ensembl chr10:42,006,651...42,009,213
JBrowse link
G Hapln1 hyaluronan and proteoglycan link protein 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of HAPLN1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:20,631,640...20,696,388
Ensembl chr 2:20,631,640...20,693,777
JBrowse link
G Hdlbp high density lipoprotein binding protein decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of HDLBP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HDLBP mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:93,948,099...94,018,040
Ensembl chr 9:93,949,913...94,018,048
JBrowse link
G Herpud1 homocysteine inducible ER protein with ubiquitin like domain 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HERPUD1 mRNA CTD PMID:27188386 NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424
JBrowse link
G Hes5 hes family bHLH transcription factor 5 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of HES5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:165,522,138...165,523,684
Ensembl chr 5:165,522,234...165,523,001
JBrowse link
G Hexa hexosaminidase subunit alpha increases expression
multiple interactions
ISO mercuric bromide results in increased expression of HEXA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HEXA mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:59,936,526...59,961,654
Ensembl chr 8:59,936,660...59,962,013
JBrowse link
G Hgsnat heparan-alpha-glucosaminide N-acetyltransferase decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of HGSNAT mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HGSNAT mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:66,105,233...66,137,444
Ensembl chr16:66,105,181...66,136,138
JBrowse link
G Hif3a hypoxia inducible factor 3 subunit alpha multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HIF3A mRNA CTD PMID:27188386 NCBI chr 1:77,718,110...77,750,448
Ensembl chr 1:77,722,471...77,749,758
JBrowse link
G Hist1h2bd histone cluster 1 H2B family member D multiple interactions
decreases expression
ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC5 mRNA
mercuric bromide results in decreased expression of H2BC5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:42,792,887...42,793,268 JBrowse link
G Hivep1 HIVEP zinc finger 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HIVEP1 mRNA CTD PMID:27188386 NCBI chr17:22,585,016...22,714,517
Ensembl chr17:22,585,016...22,711,956
JBrowse link
G Hmgcs1 3-hydroxy-3-methylglutaryl-CoA synthase 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of HMGCS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCS1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
JBrowse link
G Hmox1 heme oxygenase 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of HMOX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMOX1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Hnmt histamine N-methyltransferase increases expression
multiple interactions
ISO mercuric bromide results in increased expression of HNMT mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HNMT mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:6,591,804...6,623,821
Ensembl chr 3:6,591,463...6,624,012
JBrowse link
G Hnrnpr heterogeneous nuclear ribonucleoprotein R decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of HNRNPR mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HNRNPR mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:148,542,999...148,574,888
Ensembl chr 5:148,543,044...148,574,867
JBrowse link
G Hpgd 15-hydroxyprostaglandin dehydrogenase increases expression
multiple interactions
ISO mercuric bromide results in increased expression of HPGD mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPGD mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228
JBrowse link
G Hrh3 histamine receptor H3 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of HRH3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRH3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:167,191,551...167,196,642
Ensembl chr 3:167,191,558...167,196,642
JBrowse link
G Hrk harakiri, BCL2 interacting protein increases expression
multiple interactions
ISO mercuric bromide results in increased expression of HRK mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRK mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:38,387,484...38,409,652 JBrowse link
G Hs3st1 heparan sulfate-glucosamine 3-sulfotransferase 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of HS3ST1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HS3ST1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:71,185,826...71,223,263
Ensembl chr14:71,185,682...71,223,248
JBrowse link
G Hs3st3a1 heparan sulfate-glucosamine 3-sulfotransferase 3A1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of HS3ST3A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3A1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:49,092,850...49,180,676
Ensembl chr10:49,094,026...49,180,676
JBrowse link
G Hs3st3b1 heparan sulfate-glucosamine 3-sulfotransferase 3B1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of HS3ST3B1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3B1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:48,561,473...48,593,970
Ensembl chr10:48,561,473...48,593,970
JBrowse link
G Hsd17b8 hydroxysteroid (17-beta) dehydrogenase 8 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of HSD17B8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HSD17B8 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr20:4,826,725...4,828,742
Ensembl chr20:4,822,026...4,828,742
JBrowse link
G Hspa4l heat shock protein family A (Hsp70) member 4 like increases expression
multiple interactions
ISO mercuric bromide results in increased expression of HSPA4L mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:123,740,384...123,793,088
Ensembl chr 2:123,740,384...123,793,084
JBrowse link
G Hspb8 heat shock protein family B (small) member 8 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPB8 mRNA CTD PMID:27188386 NCBI chr12:40,176,405...40,205,002
Ensembl chr12:40,176,532...40,191,185
JBrowse link
G Hsph1 heat shock protein family H (Hsp110) member 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPH1 mRNA CTD PMID:27188386 NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224
JBrowse link
G Htatip2 HIV-1 Tat interactive protein 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of HTATIP2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HTATIP2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:99,473,411...99,488,632
Ensembl chr 1:99,469,245...99,488,629
JBrowse link
G Htra1 HtrA serine peptidase 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of HTRA1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HTRA1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:185,497,815...185,547,380
Ensembl chr 1:185,497,735...185,547,379
JBrowse link
G Id1 inhibitor of DNA binding 1, HLH protein increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ID1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ID1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419
JBrowse link
G Idh3a isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha increases expression
multiple interactions
ISO mercuric bromide results in increased expression of IDH3A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDH3A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084
JBrowse link
G Ids iduronate 2-sulfatase increases expression
multiple interactions
ISO mercuric bromide results in increased expression of IDS mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDS mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:149,025,977...149,046,639
Ensembl chr  X:149,025,976...149,046,663
JBrowse link
G Ier3 immediate early response 3 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IER3 mRNA CTD PMID:27188386 NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583
JBrowse link
G Ifrd1 interferon-related developmental regulator 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFRD1 mRNA CTD PMID:27188386 NCBI chr 6:57,269,395...57,317,833
Ensembl chr 6:57,269,384...57,288,990
JBrowse link
G Ift57 intraflagellar transport 57 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of IFT57 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IFT57 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:51,051,520...51,124,909
Ensembl chr11:51,059,611...51,124,812
JBrowse link
G Igfbp3 insulin-like growth factor binding protein 3 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of IGFBP3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGFBP3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
JBrowse link
G Igfbp5 insulin-like growth factor binding protein 5 decreases expression ISO mercuric bromide results in decreased expression of IGFBP5 mRNA CTD PMID:26272509 NCBI chr 9:74,452,371...74,464,953
Ensembl chr 9:74,448,382...74,465,156
JBrowse link
G Igfbp6 insulin-like growth factor binding protein 6 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGFBP6 mRNA CTD PMID:27188386 NCBI chr 7:133,276,309...133,280,944
Ensembl chr 7:133,276,234...133,280,966
JBrowse link
G Igfbp7 insulin-like growth factor binding protein 7 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of IGFBP7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGFBP7 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:30,737,414...30,797,317
Ensembl chr14:30,737,164...30,797,314
JBrowse link
G Igsf21 immunoglobin superfamily, member 21 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of IGSF21 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGSF21 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:152,287,834...152,512,174
Ensembl chr 5:152,287,835...152,512,174
JBrowse link
G Il13ra1 interleukin 13 receptor subunit alpha 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of IL13RA1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL13RA1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:115,348,860...115,408,682
Ensembl chr  X:115,348,860...115,408,681
JBrowse link
G Il1rap interleukin 1 receptor accessory protein multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL1RAP mRNA CTD PMID:27188386 NCBI chr11:74,062,999...74,199,530
Ensembl chr11:74,070,304...74,199,530
JBrowse link
G Il6 interleukin 6 increases expression ISO mercuric bromide results in increased expression of IL6 mRNA CTD PMID:26272509 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Il6r interleukin 6 receptor increases expression
multiple interactions
ISO mercuric bromide results in increased expression of IL6R mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL6R mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536
JBrowse link
G Inf2 inverted formin 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of INF2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INF2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:131,649,162...131,675,944
Ensembl chr 6:131,649,211...131,675,941
JBrowse link
G Inhbe inhibin subunit beta E increases expression
multiple interactions
ISO mercuric bromide results in increased expression of INHBE mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBE mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:63,177,558...63,178,983
Ensembl chr 7:63,176,219...63,179,172
JBrowse link
G Ino80d INO80 complex subunit D decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of INO80D mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of INO80D mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:64,447,075...64,514,013
Ensembl chr 9:64,457,165...64,515,242
JBrowse link
G Inpp5d inositol polyphosphate-5-phosphatase D increases expression
multiple interactions
ISO mercuric bromide results in increased expression of INPP5D mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP5D mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:88,287,680...88,392,748
Ensembl chr 9:88,287,677...88,392,746
JBrowse link
G Insig1 insulin induced gene 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of INSIG1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of INSIG1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
JBrowse link
G Iqce IQ motif containing E decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of IQCE mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IQCE mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:13,943,290...13,982,708
Ensembl chr12:13,943,487...13,982,693
JBrowse link
G Irs1 insulin receptor substrate 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of IRS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRS1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
JBrowse link
G Isl1 ISL LIM homeobox 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISL1 mRNA CTD PMID:27188386 NCBI chr 2:48,079,412...48,090,704
Ensembl chr 2:48,080,522...48,095,584
JBrowse link
G Isl2 ISL LIM homeobox 2 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISL2 mRNA CTD PMID:27188386 NCBI chr 8:55,923,805...55,928,790
Ensembl chr 8:55,923,805...55,928,790
JBrowse link
G Ist1 IST1 factor associated with ESCRT-III multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IST1 mRNA CTD PMID:27188386 NCBI chr19:37,648,840...37,671,019
Ensembl chr19:37,648,095...37,670,956
JBrowse link
G Itga4 integrin subunit alpha 4 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of ITGA4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGA4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:64,162,764...64,235,010
Ensembl chr 3:64,163,085...64,233,715
JBrowse link
G Itga8 integrin subunit alpha 8 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ITGA8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA8 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:75,304,004...75,501,510
Ensembl chr17:75,304,008...75,501,510
JBrowse link
G Itgb6 integrin subunit beta 6 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ITGB6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGB6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:45,046,295...45,170,532
Ensembl chr 3:45,048,044...45,121,671
JBrowse link
G Itih5 inter-alpha-trypsin inhibitor heavy chain 5 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ITIH5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITIH5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:68,248,115...68,352,216
Ensembl chr17:68,252,128...68,352,207
JBrowse link
G Itm2a integral membrane protein 2A increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ITM2A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITM2A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:72,486,383...72,492,344
Ensembl chr  X:72,486,381...72,492,363
JBrowse link
G Itm2b integral membrane protein 2B increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ITM2B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITM2B mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:48,545,998...48,568,904
Ensembl chr15:48,546,001...48,568,917
JBrowse link
G Itpr2 inositol 1,4,5-trisphosphate receptor, type 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ITPR2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPR2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:179,028,594...179,434,657
Ensembl chr 4:179,027,281...179,404,164
JBrowse link
G Jam2 junctional adhesion molecule 2 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of JAM2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JAM2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:23,830,820...23,880,071
Ensembl chr11:23,831,106...23,880,063
JBrowse link
G Jazf1 JAZF zinc finger 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of JAZF1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JAZF1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:81,879,501...82,183,241
Ensembl chr 4:81,881,061...82,183,100
JBrowse link
G Jph4 junctophilin 4 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of JPH4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JPH4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:28,579,579...28,588,903
Ensembl chr15:28,571,568...28,587,573
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JUN mRNA CTD PMID:27188386 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
JBrowse link
G Kat6a lysine acetyltransferase 6A decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of KAT6A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT6A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:69,084,914...69,165,923
Ensembl chr16:69,084,914...69,163,606
JBrowse link
G Katnbl1 katanin regulatory subunit B1 like 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of KATNBL1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KATNBL1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:99,183,748...99,225,789
Ensembl chr 3:99,183,716...99,225,786
JBrowse link
G Kcnj12 potassium inwardly-rectifying channel, subfamily J, member 12 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of KCNJ12 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ12 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:45,696,621...45,745,528
Ensembl chr10:45,696,849...45,745,492
JBrowse link
G Kcnk1 potassium two pore domain channel subfamily K member 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of KCNK1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNK1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:53,959,411...53,997,726
Ensembl chr19:53,959,657...53,997,724
JBrowse link
G Kcnk10 potassium two pore domain channel subfamily K member 10 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of KCNK10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:117,690,052...117,826,120
Ensembl chr 6:117,694,222...117,825,695
JBrowse link
G Kcnq2 potassium voltage-gated channel subfamily Q member 2 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of KCNQ2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNQ2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:168,194,776...168,253,831
Ensembl chr 3:168,195,357...168,275,071
JBrowse link
G Kctd1 potassium channel tetramerization domain containing 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of KCTD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:6,122,390...6,316,434
Ensembl chr18:6,122,390...6,317,393
JBrowse link
G Kctd12 potassium channel tetramerization domain containing 12 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of KCTD12 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD12 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:79,800,077...79,806,064
Ensembl chr15:79,801,191...79,806,282
JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of KEAP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KEAP1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
JBrowse link
G Kif1a kinesin family member 1A multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIF1A mRNA CTD PMID:27188386 NCBI chr 9:93,563,033...93,647,412
Ensembl chr 9:93,563,045...93,647,480
JBrowse link
G Kitlg KIT ligand increases expression
multiple interactions
ISO mercuric bromide results in increased expression of KITLG mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KITLG mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214
JBrowse link
G Klf11 Kruppel-like factor 11 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of KLF11 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLF11 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:41,285,699...41,297,548
Ensembl chr 6:41,285,842...41,297,550
JBrowse link
G Klf5 Kruppel-like factor 5 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of KLF5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445
JBrowse link
G Klf6 Kruppel-like factor 6 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of KLF6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
JBrowse link
G Klf9 Kruppel-like factor 9 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF9 mRNA CTD PMID:27188386 NCBI chr 1:220,700,108...220,725,029
Ensembl chr 1:220,700,108...220,725,037
JBrowse link
G Klhdc8a kelch domain containing 8A decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of KLHDC8A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHDC8A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:43,735,702...43,744,277
Ensembl chr13:43,736,192...43,744,277
JBrowse link
G Klhl21 kelch-like family member 21 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLHL21 mRNA CTD PMID:27188386 NCBI chr 5:162,514,888...162,523,545
Ensembl chr 5:162,514,765...162,523,545
JBrowse link
G Klhl4 kelch-like family member 4 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLHL4 mRNA CTD PMID:27188386 NCBI chr  X:79,429,193...79,719,482
Ensembl chr  X:79,622,113...79,719,480
JBrowse link
G Klhl5 kelch-like family member 5 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHL5 mRNA CTD PMID:27188386 NCBI chr14:43,144,254...43,206,192
Ensembl chr14:43,144,257...43,184,238
JBrowse link
G Klk8 kallikrein related-peptidase 8 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of KLK8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLK8 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:94,251,803...94,258,646
Ensembl chr 1:94,251,803...94,258,646
JBrowse link
G Kndc1 kinase non-catalytic C-lobe domain containing 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of KNDC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KNDC1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:194,689,962...194,738,353
Ensembl chr 1:194,690,135...194,738,362
JBrowse link
G Kras KRAS proto-oncogene, GTPase decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of KRAS mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KRAS mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:178,185,418...178,218,484 JBrowse link
G Krt18 keratin 18 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of KRT18 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166
JBrowse link
G Krt8 keratin 8 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of KRT8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT8 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728
JBrowse link
G Lacc1 laccase domain containing 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of LACC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACC1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:52,390,267...52,407,630
Ensembl chr15:52,395,183...52,407,545
JBrowse link
G Lactb lactamase, beta multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACTB mRNA CTD PMID:27188386 NCBI chr 8:67,571,504...67,587,592
Ensembl chr 8:67,571,500...67,587,539
JBrowse link
G Lamc2 laminin subunit gamma 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of LAMC2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMC2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:65,284,664...65,344,200
Ensembl chr13:65,284,664...65,344,200
JBrowse link
G Lamp2 lysosomal-associated membrane protein 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of LAMP2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMP2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:117,173,097...117,222,090
Ensembl chr  X:117,057,606...117,260,522
JBrowse link
G Layn layilin increases expression
multiple interactions
ISO mercuric bromide results in increased expression of LAYN mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAYN mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:51,363,928...51,384,748
Ensembl chr 8:51,367,091...51,384,330
JBrowse link
G Lgals3 galectin 3 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of LGALS3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025
JBrowse link
G Lgals8 galectin 8 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of LGALS8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS8 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:58,024,652...58,052,764
Ensembl chr17:58,028,105...58,052,764
JBrowse link
G Lhfpl4 LHFPL tetraspan subfamily member 4 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of LHFPL4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHFPL4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:146,313,539...146,340,113
Ensembl chr 4:146,313,541...146,340,463
JBrowse link
G Lhfpl6 LHFPL tetraspan subfamily member 6 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of LHFPL6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHFPL6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:137,126,485...137,324,442
Ensembl chr 2:137,126,509...137,324,443
JBrowse link
G Lhx2 LIM homeobox 2 decreases expression ISO mercuric bromide results in decreased expression of LHX2 mRNA CTD PMID:26272509 NCBI chr 3:22,113,619...22,143,909
Ensembl chr 3:22,126,007...22,143,908
JBrowse link
G Lhx4 LIM homeobox 4 increases expression ISO mercuric bromide results in increased expression of LHX4 mRNA CTD PMID:26272509 NCBI chr13:67,873,618...67,927,003
Ensembl chr13:67,877,109...67,927,003
JBrowse link
G Lhx8 LIM homeobox 8 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA CTD PMID:27188386 NCBI chr 2:243,244,958...243,269,631
Ensembl chr 2:243,244,961...243,269,416
JBrowse link
G Lifr LIF receptor subunit alpha increases expression
multiple interactions
ISO mercuric bromide results in increased expression of LIFR mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:56,224,393...56,292,988
Ensembl chr 2:56,250,120...56,286,699
JBrowse link
G Lim2 lens intrinsic membrane protein 2 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIM2 mRNA CTD PMID:27188386 NCBI chr 1:93,837,597...93,843,769
Ensembl chr 1:93,837,597...93,843,769
JBrowse link
G Limch1 LIM and calponin homology domains 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIMCH1 mRNA CTD PMID:27188386 NCBI chr14:41,112,579...41,425,185
Ensembl chr14:41,114,803...41,425,191
JBrowse link
G Lix1 limb and CNS expressed 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of LIX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIX1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:58,128,961...58,187,554
Ensembl chr 1:58,128,961...58,185,964
JBrowse link
G Lman1 lectin, mannose-binding, 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of LMAN1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMAN1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:59,508,996...59,530,873
Ensembl chr18:59,508,996...59,530,851
JBrowse link
G Lmna lamin A/C increases expression
multiple interactions
ISO mercuric bromide results in increased expression of LMNA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMNA mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423
JBrowse link
G Lmo1 LIM domain only 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of LMO1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:163,132,338...163,168,521
Ensembl chr 1:163,132,339...163,168,522
JBrowse link
G Lmo3 LIM domain only 3 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of LMO3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:171,234,686...171,297,677
Ensembl chr 4:171,234,696...171,292,222
JBrowse link
G Lmo7 LIM domain 7 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of LMO7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMO7 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:78,567,029...78,769,833
Ensembl chr15:78,567,023...78,769,783
JBrowse link
G Lnx1 ligand of numb-protein X 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of LNX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:33,514,429...33,617,086
Ensembl chr14:33,514,436...33,617,086
JBrowse link
G LOC100361087 hypothetical LOC100361087 multiple interactions
decreases expression
ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF226 mRNA
mercuric bromide results in decreased expression of C1ORF226 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:82,533,538...82,538,676
Ensembl chr13:82,530,577...82,820,949
JBrowse link
G LOC103690190 histone H2A type 1-E decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of H2AC6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2AC6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:42,707,863...42,708,420 JBrowse link
G LOC498368 similar to RIKEN cDNA 0610040J01 increases expression ISO mercuric bromide results in increased expression of C4ORF19 mRNA CTD PMID:26272509 NCBI chr14:44,387,386...44,478,344
Ensembl chr14:44,387,393...44,478,041
JBrowse link
G LOC691113 hypothetical protein LOC691113 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of C2ORF68 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2ORF68 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:104,402,553...104,408,317
Ensembl chr 4:104,402,588...104,408,320
JBrowse link
G Lpar3 lysophosphatidic acid receptor 3 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of LPAR3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LPAR3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:235,125,234...235,193,916
Ensembl chr 2:235,149,065...235,193,357
JBrowse link
G Lpar6 lysophosphatidic acid receptor 6 increases expression ISO mercuric bromide results in increased expression of LPAR6 mRNA CTD PMID:26272509 NCBI chr15:48,416,548...48,418,357
Ensembl chr15:48,416,544...48,422,331
JBrowse link
G Lrp10 LDL receptor related protein 10 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of LRP10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRP10 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:27,921,105...27,927,507
Ensembl chr15:27,920,259...27,927,505
JBrowse link
G Lrrc34 leucine rich repeat containing 34 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of LRRC34 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC34 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:112,752,294...112,774,463
Ensembl chr 2:112,754,578...112,774,459
JBrowse link
G Lrrc3b leucine rich repeat containing 3B decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of LRRC3B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC3B mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:9,973,556...10,050,891
Ensembl chr15:9,969,983...10,051,066
JBrowse link
G Lrrn4 leucine rich repeat neuronal 4 increases expression ISO mercuric bromide results in increased expression of LRRN4 mRNA CTD PMID:26272509 NCBI chr 3:120,138,093...120,150,877
Ensembl chr 3:120,139,410...120,150,831
JBrowse link
G Lsamp limbic system-associated membrane protein decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of LSAMP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LSAMP mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:58,547,533...60,717,329
Ensembl chr11:58,554,805...60,717,029
JBrowse link
G Ly6k lymphocyte antigen 6 family member K increases expression
multiple interactions
ISO mercuric bromide results in increased expression of LY6K mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LY6K mRNA
CTD PMID:26272509 PMID:27188386
G Lyve1 lymphatic vessel endothelial hyaluronan receptor 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of LYVE1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYVE1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:164,962,872...164,976,309
Ensembl chr 1:164,962,872...164,976,309
JBrowse link
G Lzts1 leucine zipper tumor suppressor 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LZTS1 mRNA CTD PMID:27188386 NCBI chr16:20,542,756...20,598,204
Ensembl chr16:20,542,809...20,598,203
JBrowse link
G Mab21l2 mab-21 like 2 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of MAB21L2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAB21L2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:171,946,573...171,949,655
Ensembl chr 2:171,946,573...171,949,655
JBrowse link
G Macc1 MET transcriptional regulator MACC1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of MACC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:140,352,690...140,430,255
Ensembl chr 6:140,352,755...140,430,255
JBrowse link
G Macroh2a1 macroH2A.1 histone decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of MACROH2A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:8,479,331...8,542,071
Ensembl chr17:8,479,372...8,542,072
JBrowse link
G Mafb MAF bZIP transcription factor B multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAFB mRNA CTD PMID:27188386 NCBI chr 3:148,998,111...149,000,031
Ensembl chr 3:148,998,122...149,000,031
JBrowse link
G Maff MAF bZIP transcription factor F multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAFF mRNA CTD PMID:27188386 NCBI chr 7:110,912,499...110,923,851
Ensembl chr 7:110,912,499...110,923,851
JBrowse link
G Mafg MAF bZIP transcription factor G increases expression
multiple interactions
ISO mercuric bromide results in increased expression of MAFG mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAFG mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:105,903,307...105,911,845
Ensembl chr10:105,903,237...105,912,026
JBrowse link
G Mal2 mal, T-cell differentiation protein 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of MAL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAL2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:85,900,453...85,933,433
Ensembl chr 7:85,900,453...85,933,429
JBrowse link
G Man1a1 mannosidase, alpha, class 1A, member 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of MAN1A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAN1A1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr20:33,202,509...33,385,747
Ensembl chr20:33,202,517...33,385,824
JBrowse link
G Man1c1 mannosidase, alpha, class 1C, member 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of MAN1C1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAN1C1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:146,774,282...146,913,257
Ensembl chr 5:146,775,842...146,913,421
JBrowse link
G Map1a microtubule-associated protein 1A increases expression
multiple interactions
ISO mercuric bromide results in increased expression of MAP1A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP1A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:108,263,217...108,283,936
Ensembl chr 3:108,263,151...108,282,899
JBrowse link
G Map2k6 mitogen-activated protein kinase kinase 6 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of MAP2K6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP2K6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293
JBrowse link
G Map3k14 mitogen-activated protein kinase kinase kinase 14 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K14 mRNA CTD PMID:27188386 NCBI chr10:88,165,349...88,215,558
Ensembl chr10:88,165,351...88,215,523
JBrowse link
G Map3k5 mitogen-activated protein kinase kinase kinase 5 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K5 mRNA CTD PMID:27188386 NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
JBrowse link
G Map4 microtubule-associated protein 4 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of MAP4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:109,925,233...110,064,370
Ensembl chr 8:109,925,575...110,064,362
JBrowse link
G Map4k4 mitogen-activated protein kinase kinase kinase kinase 4 increases expression ISO mercuric bromide results in increased expression of MAP4K4 mRNA CTD PMID:26272509 NCBI chr 9:42,200,708...42,326,708
Ensembl chr 9:42,200,278...42,326,698
JBrowse link
G Map6 microtubule-associated protein 6 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP6 mRNA CTD PMID:27188386 NCBI chr 1:153,568,019...153,634,415
Ensembl chr 1:153,568,368...153,634,414
JBrowse link
G Map7 microtubule-associated protein 7 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of MAP7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:14,910,433...15,037,574
Ensembl chr 1:14,910,551...15,037,574
JBrowse link
G Mapk10 mitogen activated protein kinase 10 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of MAPK10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAPK10 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:6,497,662...6,790,109
Ensembl chr14:6,497,707...6,786,201
JBrowse link
G Marveld3 MARVEL domain containing 3 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of MARVELD3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MARVELD3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:37,908,727...37,923,420
Ensembl chr19:37,905,638...37,923,420
JBrowse link
G Mast4 microtubule associated serine/threonine kinase family member 4 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of MAST4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAST4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:33,893,241...34,483,600
Ensembl chr 2:33,894,436...34,483,723
JBrowse link
G Mbd2 methyl-CpG binding domain protein 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of MBD2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBD2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:64,174,002...64,240,795
Ensembl chr18:64,174,002...64,240,794
JBrowse link
G Mbnl3 muscleblind-like splicing regulator 3 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of MBNL3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:130,641,942...130,737,179
Ensembl chr  X:130,648,538...130,737,056
JBrowse link
G Mboat1 membrane bound O-acyltransferase domain containing 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of MBOAT1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBOAT1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:34,331,413...34,445,088
Ensembl chr17:34,331,422...34,445,088
JBrowse link
G Mcc MCC regulator of WNT signaling pathway increases expression
multiple interactions
ISO mercuric bromide results in increased expression of MCC mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCC mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:36,794,206...37,266,237
Ensembl chr18:36,798,372...37,266,819
JBrowse link
G Mcm7 minichromosome maintenance complex component 7 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of MCM7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MCM7 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063
JBrowse link
G Mcoln3 mucolipin TRP cation channel 3 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of MCOLN3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:234,966,010...235,043,047
Ensembl chr 2:234,966,010...235,043,047
JBrowse link
G Mctp1 multiple C2 and transmembrane domain containing 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of MCTP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCTP1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:6,071,408...6,761,833
Ensembl chr 2:6,065,808...6,761,833
JBrowse link
G Mdm2 MDM2 proto-oncogene increases expression
multiple interactions
ISO mercuric bromide results in increased expression of MDM2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDM2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
JBrowse link
G Me1 malic enzyme 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of ME1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ME1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304
JBrowse link
G Megf10 multiple EGF-like domains 10 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of MEGF10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEGF10 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:50,605,231...50,755,441
Ensembl chr18:50,605,656...50,754,456
JBrowse link
G Meiob meiosis specific with OB-fold decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of MEIOB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEIOB mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:13,833,170...13,865,684
Ensembl chr10:13,833,750...13,865,046
JBrowse link
G Meltf melanotransferrin decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of MELTF mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MELTF mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:68,884,446...68,906,300
Ensembl chr11:68,884,446...68,906,300
JBrowse link
G Meox1 mesenchyme homeobox 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of MEOX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:86,818,450...86,837,563
Ensembl chr10:86,818,478...86,837,660
JBrowse link
G Mettl7a methyltransferase like 7A increases expression
multiple interactions
ISO mercuric bromide results in increased expression of METTL7A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of METTL7A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:131,452,099...131,460,154
Ensembl chr 7:131,451,641...131,460,154
JBrowse link
G Mfap3l microfibril associated protein 3 like decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of MFAP3L mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:29,411,643...29,454,665
Ensembl chr16:29,415,849...29,430,863
JBrowse link
G Mfap5 microfibril associated protein 5 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MFAP5 mRNA CTD PMID:27188386 NCBI chr 4:155,727,925...155,750,458
Ensembl chr 4:155,727,925...155,750,458
JBrowse link
G Mfng MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of MFNG mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:110,310,810...110,328,653
Ensembl chr 7:110,310,812...110,328,653
JBrowse link
G Mgarp mitochondria-localized glutamic acid-rich protein multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MGARP mRNA CTD PMID:27188386 NCBI chr 2:135,431,283...135,439,425
Ensembl chr 2:135,431,283...135,439,612
JBrowse link
G Mif4gd MIF4G domain containing decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of MIF4GD mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIF4GD mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:100,847,168...100,852,166 JBrowse link
G Mitf melanocyte inducing transcription factor increases expression
multiple interactions
ISO mercuric bromide results in increased expression of MITF mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MITF mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:130,409,020...130,621,145
Ensembl chr 4:130,409,217...130,621,145
JBrowse link
G Mmab metabolism of cobalamin associated B decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of MMAB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MMAB mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:42,159,109...42,172,496
Ensembl chr12:42,159,089...42,172,490
JBrowse link
G Mmp14 matrix metallopeptidase 14 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of MMP14 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MMP14 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864
JBrowse link
G Mmp16 matrix metallopeptidase 16 decreases expression ISO mercuric bromide results in decreased expression of MMP16 mRNA CTD PMID:26272509 NCBI chr 5:31,312,280...31,556,276
Ensembl chr 5:31,312,280...31,548,388
JBrowse link
G Mnx1 motor neuron and pancreas homeobox 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of MNX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MNX1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:5,866,506...5,871,465
Ensembl chr 4:5,866,506...5,871,465
JBrowse link
G Mpzl2 myelin protein zero-like 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of MPZL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MPZL2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:45,348,285...45,359,298
Ensembl chr 8:45,348,285...45,359,298
JBrowse link
G Mrgprf MAS related GPR family member F multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MRGPRF mRNA CTD PMID:27188386 NCBI chr 1:200,464,100...200,473,588
Ensembl chr 1:200,463,973...200,473,660
JBrowse link
G Mrpl4 mitochondrial ribosomal protein L4 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MRPL4 mRNA CTD PMID:27188386 NCBI chr 8:19,539,593...19,545,608
Ensembl chr 8:19,539,593...19,545,608
JBrowse link
G Msrb3 methionine sulfoxide reductase B3 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of MSRB3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MSRB3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:56,260,985...56,426,004
Ensembl chr 7:56,303,308...56,425,496
JBrowse link
G Msx1 msh homeobox 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of MSX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:72,961,170...72,964,970
Ensembl chr14:72,961,148...72,964,966
JBrowse link
G Msx2 msh homeobox 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of MSX2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:11,097,214...11,102,879
Ensembl chr17:11,097,103...11,102,879
JBrowse link
G Mt1-ps3 metallothionein 1, pseudogene 3 multiple interactions
increases expression
ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1G mRNA
mercuric bromide results in increased expression of MT1G mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:74,786,652...74,787,040
Ensembl chr17:74,786,654...74,787,135
JBrowse link
G Mt1m metallothionein 1M multiple interactions
increases expression
ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1HL1 mRNA
mercuric bromide results in increased expression of MT1HL1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr20:3,159,023...3,159,401
Ensembl chr 5:119,728,811...119,730,073
Ensembl chr19:119,728,811...119,730,073
JBrowse link
G Mt2A metallothionein 2A increases expression
multiple interactions
ISO mercuric bromide results in increased expression of MT2A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT2A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
JBrowse link
G Mtss1 MTSS I-BAR domain containing 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of MTSS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MTSS1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:90,488,751...90,628,007
Ensembl chr 7:90,488,754...90,627,968
JBrowse link
G Muc15 mucin 15, cell surface associated increases expression
multiple interactions
ISO mercuric bromide results in increased expression of MUC15 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC15 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:97,294,728...97,308,641
Ensembl chr 3:97,294,783...97,307,090
JBrowse link
G Mycl MYCL proto-oncogene, bHLH transcription factor decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of MYCL mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYCL mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:135,274,713...135,281,584
Ensembl chr 5:135,274,748...135,281,582
JBrowse link
G Myct1 myc target 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCT1 mRNA CTD PMID:27188386 NCBI chr 1:42,018,137...42,029,410
Ensembl chr 1:42,018,137...42,029,410
JBrowse link
G Mylk myosin light chain kinase decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of MYLK mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261
JBrowse link
G Myo10 myosin X increases expression
multiple interactions
ISO mercuric bromide results in increased expression of MYO10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO10 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:76,100,962...76,304,164
Ensembl chr 2:76,100,987...76,303,030
JBrowse link
G Myo1d myosin ID increases expression
multiple interactions
ISO mercuric bromide results in increased expression of MYO1D mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO1D mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:65,489,153...65,765,812
Ensembl chr10:65,489,154...65,766,349
JBrowse link
G Myof myoferlin increases expression
multiple interactions
ISO mercuric bromide results in increased expression of MYOF mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOF mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:235,673,666...235,822,413
Ensembl chr 1:235,673,666...235,822,334
JBrowse link
G N4bp2l2 NEDD4 binding protein 2-like 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of N4BP2L2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of N4BP2L2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:137,342...200,294
Ensembl chr12:103,590...197,784
JBrowse link
G Nabp1 nucleic acid binding protein 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of NABP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NABP1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:50,098,552...50,133,982
Ensembl chr 9:50,126,726...50,134,107
JBrowse link
G Nat1 N-acetyltransferase 1 increases expression ISO mercuric bromide results in increased expression of NAT1 mRNA CTD PMID:26272509 NCBI chr16:22,218,217...22,238,516
Ensembl chr16:22,208,194...22,238,520
JBrowse link
G Nav1 neuron navigator 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of NAV1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAV1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:46,866,972...47,119,368
Ensembl chr13:46,873,689...47,126,449
JBrowse link
G Ncald neurocalcin delta decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of NCALD mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:68,532,671...68,964,740
Ensembl chr 7:68,534,421...68,964,496
JBrowse link
G Ncam1 neural cell adhesion molecule 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of NCAM1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCAM1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:49,865,629...50,165,687
Ensembl chr 8:49,865,633...50,166,014
JBrowse link
G Ncan neurocan decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of NCAN mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCAN mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:19,301,969...19,328,436
Ensembl chr16:19,301,969...19,328,436
JBrowse link
G Ncoa7 nuclear receptor coactivator 7 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of NCOA7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCOA7 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:26,856,228...27,016,950
Ensembl chr 1:26,856,530...27,015,871
JBrowse link
G Ndfip2 Nedd4 family interacting protein 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of NDFIP2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NDFIP2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:82,032,366...82,087,043
Ensembl chr15:82,032,366...82,086,317
JBrowse link
G Ndp norrin cystine knot growth factor NDP decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of NDP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDP mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:5,796,487...5,820,934
Ensembl chr  X:5,796,487...5,820,934
JBrowse link
G Ndst4 N-deacetylase and N-sulfotransferase 4 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NDST4 mRNA CTD PMID:27188386 NCBI chr 2:213,787,010...214,116,569
Ensembl chr 2:213,787,006...214,115,373
JBrowse link
G Ndufb1 NADH:ubiquinone oxidoreductase subunit B1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of NDUFB1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDUFB1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:121,115,649...121,124,056 JBrowse link
G Nectin4 nectin cell adhesion molecule 4 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of NECTIN4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NECTIN4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:83,802,589...83,821,711
Ensembl chr13:83,803,184...83,821,709
JBrowse link
G Nefh neurofilament heavy chain decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of NEFH mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEFH mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:79,830,362...79,840,347
Ensembl chr14:79,830,362...79,840,351
JBrowse link
G Nefl neurofilament light chain increases expression
multiple interactions
ISO mercuric bromide results in increased expression of NEFL mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFL mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
JBrowse link
G Nefm neurofilament medium chain increases expression
multiple interactions
ISO mercuric bromide results in increased expression of NEFM mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFM mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:42,360,449...42,365,753
Ensembl chr15:42,360,454...42,365,755
JBrowse link
G Neil2 nei-like DNA glycosylase 2 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of NEIL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEIL2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:37,444,676...37,454,863
Ensembl chr15:37,445,381...37,454,863
JBrowse link
G Nexmif neurite extension and migration factor decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of NEXMIF mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEXMIF mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:69,088,076...69,219,253
Ensembl chr  X:69,088,076...69,112,930
JBrowse link
G Nf1 neurofibromin 1 decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of NF1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NF1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:64,306,027...64,539,112
Ensembl chr10:64,306,301...64,536,658
JBrowse link
G Nfasc neurofascin decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of NFASC mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFASC mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:43,997,223...44,183,863
Ensembl chr13:43,997,224...44,183,880
JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of NFE2L2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFE2L2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Nfib nuclear factor I/B increases expression
multiple interactions
ISO mercuric bromide results in increased expression of NFIB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFIB mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:96,759,208...96,973,092
Ensembl chr 5:96,764,653...96,975,479
JBrowse link
G Nhlh2 nescient helix loop helix 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of NHLH2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NHLH2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:189,444,287...189,449,625
Ensembl chr 2:189,442,711...189,449,625
JBrowse link
G Nhs NHS actin remodeling regulator decreases expression
multiple interactions
ISO mercuric bromide results in decreased expression of NHS mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NHS mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:32,551,974...32,892,961
Ensembl chr  X:32,552,026...32,889,992
JBrowse link
G Niban1 niban apoptosis regulator 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of NIBAN1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NIBAN1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:63,674,240...63,827,748
Ensembl chr13:63,674,171...63,827,729
JBrowse link
G Nipal2 NIPA-like domain containing 2 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of NIPAL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NIPAL2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:65,774,477...65,884,807
Ensembl chr 7:65,774,477...65,884,807
JBrowse link
G Nkain3 Sodium/potassium transporting ATPase interacting 3 multiple interactions
decreases expression
ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NKAIN3 mRNA
mercuric bromide results in decreased expression of NKAIN3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:33,613,720...34,310,090
Ensembl chr 5:33,623,713...34,309,381
JBrowse link
G Nln neurolysin increases expression
multiple interactions
ISO mercuric bromide results in increased expression of NLN mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NLN mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:35,133,634...35,232,927
Ensembl chr 2:35,134,145...35,232,914
JBrowse link
G Nlrx1 NLR family member X1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLRX1 mRNA CTD PMID:27188386 NCBI chr 8:44,588,476...44,606,678
Ensembl chr 8:44,590,048...44,606,484
JBrowse link
G Nme8 NME/NM23 family member 8 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of NME8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NME8 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:45,237,022...45,304,948
Ensembl chr17:45,238,120...45,304,948
JBrowse link
G Nmrk1 nicotinamide riboside kinase 1 increases expression
multiple interactions
ISO mercuric bromide results in increased expression of NMRK1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMRK1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:216,049,350...216,076,792
Ensembl chr 1:216,049,437...216,076,791
JBrowse link
G Noct nocturnin increases expression
multiple interactions
ISO mercuric bromide results in increased expression of NOCT mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOCT mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:135,271,189...135,291,407
Ensembl chr 2:135,271,189...135,291,400
JBrowse link
G Nog noggin multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] affects the expression of ARAP2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of A1BG mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABCC4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABHD14A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ACTN3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAMTS2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADCYAP1R1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AFAP1L2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AFDN-DT mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AOX1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APBA2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APCDD1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGEF25 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGEF9 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARL9 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARRDC2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARX mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASIC1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASPHD1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASTN1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATL3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP2B1-AS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP8A1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B9D1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCO1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEND4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEST4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BOC mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BST2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C11ORF96 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF226 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2ORF68 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C3ORF70 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C4ORF47 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CA4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACHD1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAMK2N1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCBE1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC102A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC113 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC136 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC177 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNG2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CD40 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH7 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH9 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDK19 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CELF5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP300 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP91 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CHRDL1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLEC18A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNFN mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNOT4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTNAP3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTNAP3P2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COPS8 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSPG5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTDSP1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUL3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUTALP mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CXCR4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAB1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCLK2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCX mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DHRS11 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DICER1-AS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIPK1C mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DOCK6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DOCK7 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DRD4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DSTYK mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EEF1AKMT2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFHC2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGFL7 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EID3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF4E3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERAP1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERICH1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERO1B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EVC2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EXD3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM124A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM149A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM222A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO9 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZ1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FHOD3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FKBP5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRMD3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRZB mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GABRA5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAL mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALNT10 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALNT14 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAS2L1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GCNT1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GDAP1L1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNAS-AS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNE mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNG8 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPM6B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR153 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR27 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRAMD1C mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIN2A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GSTM2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GUCA1A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2AC6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC21 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4